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1
CHAPTER 1 - INTRODUCTION

1.1

Gene expression by Histone Deacetylase (HDAC) proteins
The nucleosome is a unit of DNA packaged around a histone protein core

(Figure 1.1).1 The four core histone proteins (histone octomers, pink) are
wrapped by the DNA double helix (gray), which form chromosomes (violet)
through highly condensed nucleosomes. The nucleosomes carry epigenetically
inherited information in the covalent modifications of the core histones. Covalent
modifications of lysine residues located on histone N-terminal tails alter gene
expression.

1

Figure 1.1 Epigenetic mechanisms. Histone octomers (pink), DNA double stand (gray), and
chromosomes (violet). Reused with permission
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Among the covalent modifications, the acetylation status of histone lysines
is

governed

by

histone

deacetylase

(HDAC)

proteins

and

histone

acetyltransferase (HAT) proteins and is in equilibrium (Figure 1.2). HDAC and
HAT proteins are two key enzymes that regulate gene transcription. The neutral,
acetylated lysine allows DNA to interact with transcription factors to promote
gene expression. Deacetylated positively charged lysine residues interact with
the negatively charged phosphate backbone of DNA. The tight electrostatic
interaction between the additional lysine residues and the negatively charged
DNA backbone prevents activation with gene transcription. The overexpression
of HDAC proteins shifts the equilibrium to the unmodified state and results in
aberrant transcription in some cancer cells.2 More specifically, overexpression of
HDAC proteins induces repression of transcription and alteration in the
accessibility of genes to transcriptional proteins causes reduced gene
expression. Since decreasing gene expression can cause a variety of diseases,
including cancers, the family of HDAC proteins has been studied.

Figure 1.2 The equilibrium activities of histone acetyltransferase (HAT) and deacetylase (HDAC)
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1.2

HDAC protein family
The HDAC protein family consists of 18 members and is divided into four

classes based on size, cellular localization, number of catalytic active site, and
homology to yeast HDAC protein (Table 1.1).3 Class I includes HDAC1, HDAC2,
HDAC3, and HDAC8. Class II includes HDAC4, HDAC5, HDAC6, HDAC7,
HDAC9, and HDAC10. Class IV includes HDAC11 as the sole member because
it displays similarities to both class I and II. Class III are NAD +-dependent
proteins, referred to as sirtuins (SIRT 1-7).4 Class I, II, and IV are metal iondependant proteins and are sensitive to the inhibitors in this dissertation.
Table 1.1. HDAC family
+

Metal ion-dependent

NAD -dependent

Class I

Class II

Class IV

Class III

HDAC1

HDAC4

HDAC11

SIRT (1-7)

HDAC2

HDAC5

HDAC3

HDAC6

HDAC8

HDAC7
HDAC9
HDAC10

Class I HDAC proteins (HDACs) are found in cancers, including ovarian
(HDAC1, 2, and 3),5 gastric (HDAC2),6 and lung cancers (HDAC1 and HDAC3).7
Class I HDACs are produced at higher levels in ovarian cancers compared to
normal ovarian tissues, as assessed using small interfering RNA methodology.5
Strong expression of HDAC2 was found in 44 out of a total of 71 gastric tumors.6
HDAC3 is elevated in 92% of squamous cell lung carcinomas, as assessed using
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immunoblot analysis.7 HDAC8 is involved in acute myeloid leukemia (AML).8 A
common form of AML results from an abnormal fusion protein, Inv1, that binds
HDAC 8. Overexpression of class II HDAC6 is observed in breast and ovarian
cancer tissues.9 Cell motility was increased by transfecting at HDAC6 expression
plasmid into the breast cancer MCF-7 cells. Class II HDAC 10 protein is involved
in the formation of tumors of skeletal muscle.10 HDAC10 was detected at the
highest level in the skeletal muscle tumor SJRH30 rhabdomyosarcoma cell line.
The different activities that connect each HDAC isoform with cancer formation
have been given significant attention on the pharmaceutical and carcinoma
studies.5, 9
Even though each individual HDAC protein is involved in the formation of
cancers, the role of each isoform in carcinogenesis is not clear yet. Therefore,
elucidating the molecular mechanism connecting the HDAC activity of each
isoform to cancer formation would facilitate studies that lead to treatment of
diseases. To comprehensively understand the role of individual HDAC proteins in
the growth and progression of cancer, development of selective HDAC inhibitors
is required.

1.3

HDAC inhibitors
New approaches towards studying the causes and treatments of cancer

have been rigorously studied since cancers are one of major causes of death in
the United States. With a role in cancer, several HDAC inhibitor drugs are in
clinical trials for treatment of cancer.11 Specifically, suberoyl anilide hydroxamic
acid (SAHA, Vorinostat) was the first HDAC inhibitor approved by the Food and
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Drug Administration (FDA) for treatment of cutaneous T-cell lymphoma (CTCL).12
Another recent FDA-approved HDAC inhibitor is depsipeptide (romidepsin,
FK228), also for treatment for CTCL.13 Currently, most HDAC inhibitors are paninhibitors, which similarly inhibit all HDAC proteins. Therefore, developing
selective inhibitors would aid studies connecting HDAC activity to cancer
formation.
Most metal ion-dependent HDAC inhibitors, including SAHA, have a
similar structure construction consisting of a capping group that is solventexposed, a carbon linker that is surrounded by a hydrophobic tunnel, and a metal
binding moiety that is buried in the protein active site (Figure 1.3).

Figure 1.3. Structures of metal ion-dependent HDAC inhibitors

The crystal structure of SAHA bound in the active site of a bacterial
homologue support that the SAHA anilide capping group is solvent-exposed near
amino acids at the entrance of the active site, the linker positions in the
hydrophobic channel, and the hydroxamic acid is located near the zinc atom at
bottom of the active site (Figure 1.4). However, slight differences in the active
sites of the human HDAC isoforms are not known in detail because limited
crystallographic analysis is only available for HDAC2,14 HDAC3,15 HDAC4,16
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HDAC7 and HDAC8.17 Therefore, design of isoform-selective HDAC inhibitors
that inhibit only related HDAC proteins is challenging.

18

Figure 1.4. Structure of SAHA bound to an HDAC-like protein.

1.4

Reused with permission.

Inhibitor selectivity
Currently, most HDAC inhibitors, including SAHA, nonspecifically inhibit all

eleven metal ion-dependent HDAC proteins. As a promising hypothesis, the nonselective HDAC inhibitors might cause cancer patients in the clinic to suffer from
the side effects, such as fatigue, anorexia, diarrhea, and cardiac arrhythmia. 19
The clinical toxicity of selective inhibitors is unknown because there is no HDAC
isoform selective inhibitor at present. In addition, the similarity in the active sites
of the isoforms has challenged inhibitor design.20 Elucidating the relationship
between inhibitor selectivity and clinical toxicity might not only help understand
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the role of the HDAC isoform function, but also contribute to the development of
chemotherapies with fewer side effects for cancer patients.

1.5

Rationale for the synthesis of
substituents on the carbon linker

SAHA

analogues

containing

Towards creating isoform selective inhibitors, the structural regions of
HDAC inhibitors have been studied. Particularly, the capping region and metal
binding moiety have been extensively modified. 21 The influence of substituents
on the linker region is relatively less studied, although the hydrocarbon linker has
been investigated, such as varying chain length, producing points of unsaturated
chain, and adding an aryl or cyclohexyl ring.22 However, MS-275, which displays
selectivity for class I23, contains an aryl ring in the linker region (Figure 1.3). The
intra-chain aryl group structure of MS-275 suggests that selectivity may be
influenced by the structure of the linker region. We designed structure activity
relationship (SAR) studies of SAHA to investigate the role of the linker on
inhibitory activity and selectivity. Moreover, synthesis of a library of SAHA
analogs would be simple through only several steps since SAHA can be
synthesized in three steps.21c With these advantages, SAHA analogue libraries
and SAR studies led us to explore the impact of substituents in the linker region.
1.6

Specific aims
Our goal is syntheses of SAHA analogues with substituents on the linker

region. First of all, small molecule libraries of SAHA analogues would elucidate
the structural requirements of potent HDAC inhibitors. Second, developing novel
isoform or class selective inhibitors would be explored by testing the selectivity of
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the SAHA analogues. Third, screening small molecule analogues by using Fluor
de Lys™ activity assay (Enzo) would allow analyzing potency and selectivity, and
exploiting veiled interaction between specific cancer formation and selectivity.
The evaluation of these analogues will be helpful to improve chemotherapeutic
drug design.
SAHA achieved the first FDA approval among HDAC inhibitors for
cutaneous T-cell lymphoma (section 1.3). Cancer patients, however, are still
suffering from side effects.19 Because side effects may be caused by the fact that
SAHA is a pan inhibitor, the development of isoform or class-selective inhibitors
would be critical to understand the relationship between toxicity and individual
HDAC activity associated with cancer formation. Therefore, the development of
selective inhibitors has been a significant aim for biological and pharmacological
studies. Likewise, structure activity relationship (SAR) studies of small molecule
HDAC inhibitors are required because only limited numbers of the selective
inhibitors are reported. Therefore, our SAHA analogue syntheses and biological
activity studies are a fitting starting point to design selective HDAC inhibitor and
develop better chemotherapy with fewer side effects compared to current pan
inhibitors.

1.7 Development of isoform or class-selective inhibitors
Presently, a minority of examples of SAHA analogues containing
modifications on the carbon linker are reported, in spite of the promising area.
For example, a few studies of the impact of substituents on the linker have
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explored hydrophobic substituents (Figure 1.5).24 No potency improvement was
observed in ω-Alkoxy analogues Aa-Ad.24a In contrast to the ω-Alkoxy analogues
of SAHA, aminosuberoyl hydroxamic acid analogue Ae is slightly more potent
than SAHA.24b Furthermore, studies modifying the chain, such as alternating
chain length and creating an unsaturated chain, were performed as HDAC
inhibitors.22c,

25

None of the sulfonamides Ba-d (HDAC1 IC50 0.1-1 µM) having

different chain length and unsaturated chain displayed potency compared to
highly potent HDAC inhibitors, such as trichostatin A (TSA, IC50 0.005 µM) and
SAHA (HDAC1 IC50 0.096 µM).25a However, when polyaminohydroxamic acid
derivatives Ca, Cb were altered in the polyamine chain and terminal group, these
analogues promoted increased level of acetylated histones H3, H4 and
acetylated α-tubulin.25b In case of Ca, the increased level of acetylated α-tubulin
was significant while Cb had no effect on the acetylation status of α-tubulin.
Despite the modest change in chain length, distinct differences compared to
SAHA were observed. As examples of various aryl or cycloalkyl groups in the
linker, N-hydroxycarboxamides possessing the 1,4-cylohexylene group Da and
1.4-phenylene group Db were synthesized and showed only modest activities
(WST-1 IC50 77.9, 38.8 µM).20c In summary, SAR series of SAHA with
substituents have been modestly explored. As a result, in our exploratory studies
of the impact of substituents on the linker, several libraries of SAHA analogues
were synthesized on the 2, 3, 6, and 7 positions to explore potency and
selectivity (Figure 1.6).
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Figure 1.5. Structure Activity Relationship (SAR) Studies: HDAC inhibitors modified at the linker.
The examples of substituents on the linker (left). The modification of chain length, creation of
unsaturated chain, and alternation of aryl and cycloalkyl groups (right).

Figure 1.6. SAHA analogues containing substituents on the C2, C3, C6, and C7 positions

1.8 Preparation of SAHA analogues containing substituents on the linker
near the hydroxamic acid
Since the metal binding site may be partially responsible for the potency of
inhibitors, substituents on the SAHA linker area near hydroxamic acid were
introduced. Our research group initially reported the synthesis and biological
activity of C2-SAHA analogues to explore the impact of substituents near
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hydroxamic acid.26 HDAC inhibitory activities of C2-SAHA analogues were
measured using in vitro fluorescence activity assay kit (Table 1.2).
Table 1.2. HDAC inhibition by SAHA, MS-275, and the C2-SAHA analogues using HeLa cell
lysates

Compounds

R

IC50, Mª

SAHA

0.090  0.004

MS-275

3.2  0.1
Methyl

134  6

Ethyl

449  17

n-Propyl

154  7

n-Butyl

72  6

n-Pentyl

40  3

n-Hexyl

60  5

Allyl

144  9

Propargyl

87  5

Benzyl

226  11

ªValues are the mean of three experiments with standard error given.

The smallest compound, the methyl variant (IC50 134 µM), displayed 1500
and 50-fold decreased inhibition compared to SAHA (IC50 0.09 µM) and MS-275
(IC50 134 µM). Even the most potent pentyl variant showed 439 and 12-fold
decreased activity compared to SAHA and MS-275. Regardless of the
substituent size, SAHA analogues modified on the C2 position displayed
inhibition in the µM range. The high IC50 values of the C2-SAHA analogues
indicate that only limited steric size is tolerated in the HDAC active site near the

12
hydroxamic acid. In other words, bulky substituents near the solvent exposed
capping group might be more tolerated in the HDAC active site.
The tendency for significantly decreased inhibition due to substituents
near the hydroxamic acid proposed designing potent inhibitors. Specifically, the
poor inhibition of C2-SAHA analogues suggests that analogues with substituents
positioned closer to the capping group on the C3 position might be more
tolerated in the HDAC active site. However, we hypothesized that the inhibitory
activity could be unpredictable because substituents on each linker position
would have different impact in the HDAC active site channel. Besides, the
substituents on the C3 position could favorably interact with HDAC active site
since the 14 Å internal channel near the hydroxamic acid is nearer to C3 carbon
linker than C2 carbon (Figure 1.4). Therefore, a library of C3-SAHA analogues
would explore the interaction of the inhibitor with the HDAC active site for potent
and selective inhibition. The detailed synthesis and biological activity of the
library of C3-SAHA analogues are described in Chapter 2.

1.9 Preparation of SAHA analogues containing substituents on the linker
near the capping group
Small molecules with substituents on the capping group or on the linker
region near the capping group have shown great potency (nM range) and
moderate selectivity (class-selectivity) (Figure 1.7).27

Specifically, FK-228

(depsipeptide), which gained FDA approval for cutaneous T-cell lymphoma in
2009,28 displayed about 300-fold greater potency for HDAC1 and HDAC2 over
HDAC6.29 Apicidin also displayed 17-230-fold greater potency for HDAC2, 3, and

13
8 over HDAC1, 4, 6, 7, and 9.30 Trapoxin B showed HDAC1 selectivity over
HDAC6.27c The large capping groups in these HDAC inhibitors suggest that
selectivity is influenced by the capping group substituents.

Figure 1.7. Known class-selective HDAC inhibitors with bulky groups

As an example of HDAC selective inhibitor SAR studies with bulky groups
on the linker near the capping group, compound Ea (IC50 730 nM) containing the
unusual L-Aoda amino acid was selected and modified (Table 1.3). 31 The
compounds contain a ketone motif, pentyl chain, and indole group instead of
macrocycle. Although most of compounds lost 2-10 fold activity in the antiproliferation assay, the 3-piperid-1-ylpropanamide variant Eh demonstrated
improved enzyme and cellular activities. As a result, this SAR study altering the
substituents near the capping group demonstrates the structural requirement
between inhibitor structures and HDAC functions and directs the design of
specific cancer drugs.
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Table 1.3. HDAC1 and PRO (HeLa) inhibition by SAHA, MS-275, Apicidin, the compound Ea, and
derivatives

Compounds

R

HDAC1 IC50, nM

PRO (HeLa)IC50, nM

SAHA

27

460

MS-275

110

1800

Apicidin

44

290

Ea

590

730

930

7600

Ec

590

3000

Ed

480

3400

Ee

540

2500

Ef

200

1200

Eg

220

2000

Eh

190

<390

Eb

Me

Since selective inhibition could be influenced by bulky capping groups,
SAHA analogues with large substituents on the capping group or on the linker
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area near the capping group have been frequently designed, synthesized, and
evaluated (Figure 1.8).24a,

32 33

Based on a docking analysis in the crystal

structures of HDAC7 and HDAC834 of the ω-alkoxy analogue Ab, a T-shape
arrangement between substituents near the SAHA capping group and the
lipophilic pockets surrounded by phenylalanine (Phe) residues was found. A π-π
interaction between the p-methoxybenzyl moieties and Phe208 and Phe152
residues in the HDAC active site might influence isoform selectivity. Although
selective inhibition of the ω-alkoxy analogue was not improved, it had superior
antiproliferative

activity.

On

the

other

hand,

N1-hydroxy-N8-

ferrocenlyoctanediamide, JAHA, displayed picomolar inhibition against class IIa
HDAC6 (IC50 8 pM) and anticancer action in intact cells (MCF7 cell line).
Cytotoxicity against a breast cancer cell line indicated that SAHA is the most
cytotoxic compound (IC50 730nM in MCF7 breast cancer cell lines) compared to
the JAHA series (IC50 2-5µM in MCF7 breast cancer cell lines). The data suggest
that the modification of SAHA with bulky groups improves selectivity with
potency, but displays similar cytotoxicity against the cancer cell line to the parent
compound in vivo.

ω

Figure 1.8. Examples of SAHA analogues containing substituents on the linker area near
the capping group (left) and on the capping group (right)
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1.10

Novel HDAC6-selective inhibitors
We have discussed potential isoform or class-selective inhibitors, and

common efficacious compounds targeting class I-selectivity.23a,

27c, 29-30

Fewer

studies have focused on development of class II HDAC selective inhibitors. A
recent cardiac study reported that stressed myocardium showed catalytic activity
from the class IIb HDAC, HDAC6.35 Also, overexpression of HDAC6 was
detected in ovarian and breast cancer tissues.9 Since HDAC6 contains two
catalytic sites, development and design of HDAC6 selective inhibitor would
elucidate the function and mechanism of HDAC6. Tubacin is a well-known
HDAC6 selective inhibitor and displayed 4-fold greater potency for HDAC6 over
HDAC1 (Figure 1.9).36 Interestingly, the structure of tubacin has similarity with
class I selective SAHA analogues with bulky substituents at the capping group.
Slightly different modification on the capping group critically effects selectivity.
The recent SAR studies of Tubastatin A showed improved selectivity (Figure
1.9).37 Tubastatin A displayed greater than 1000-fold selectivity against HDAC6
(IC50 15 nM) compared to HDAC1 (16 µM). An extensive library of tubastatin A
indicated that tricyclic compounds displayed highly selective inhibition compared
to other compounds. The structure of Tubastatin A motivates designing new
isoform selective inhibitors. A detailed discussion of tricyclic compounds will be
discussed in Chapter 4.
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Figure 1.9. Structures of HDAC6-selective inhibitors

1.11

Evaluation of SAHA analogues containing substituents on the linker
near the hydroxamic acid and capping group
Our initial syntheses of libraries of SAHA analogues on the C2 and C3

position was achieved with substituents containing hydrophobic groups since the
carbon linker region of SAHA is surrounded by hydrophobic channel (Figure 1.4).
The data showed that only limited tolerance exists in the HDAC active site near
the metal binding moiety. In contrast, small molecules with large bulky groups
have been synthesized near or on the capping group, leading to potent
inhibitors.21b, 37-38 The outcome suggests that the area near the capping group of
HDAC inhibitors has great tolerance of steric bulky group in the HDAC active
sites, confirming our hypothesis. Therefore, our syntheses of libraries of C6 and
C7-SAHA analogues have introduced bulky substituents near the capping group
(Chapter 3 and 4). Moreover, the substituents of the SAHA analogues on the C7
position, which is located closest to the capping group, might allow monitoring
the interactions between hydrophilic substituents and the HDAC active sites
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since the substituents would be placed on the entrance of the solvent exposed
area.

1.12

Structure activity relationship (SAR) studies from matrix
metalloproteinases (MMP), another hydroxamic acid binding protein
Several series of hydrophilic substituents were attached to small molecule

inhibitors for improving anti-cancer drugs. Natural or medicinal compounds
containing nitrogen have been designed and used in clinical studies or
treatments of various diseases because of their outstanding chemical and
biological activities. For instance, the matrix metalloproteinases (MMPs), like
HDACs, are relevant enzymes involved in physiologically important processes.39
Both MMP and HDAC protein are zinc-including metalloproteinases, which
favorably interact with the hydroxamic acid moiety. Structural information on
MMPs is related to HDACs because of their relationship as metal-dependent
proteases. Since proteolysis of the extracellular matrix is found in numerous
arthritis and cancers40, several MMP inhibitors as therapeutics were discovered
and modified. Even though HDAC and MMP proteins have similar proteases
activities, SAR studies of MMP inhibitors with substituents containing nitrogen
have been more explored than with HDAC inhibitors.
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Table 1.4. Collagenase 1 (MMP1), gelatinase-A (MMP2), stromelysin 1 (MMP3), gelatinase-B
(MMP9), collagenase 3 (MMP13) inhibition by N-aryl sulfonyl homocysteine hydroxamate
analogues
IC50, nM
R

MMP1

MMP2

MMP3

MMP9

MMP13

Fa

51

0.7

1.6

0.2

0.5

Fb

20

1.2

2.2

0.2

1.1

Fc

nt

0.30

nt

0.01

nt

Fd

nt

2.3

3.7

0.5

4.5

Fe

39

0.4

1.1

0.2

0.4

Ff

nt

8.82

nt

1.88

nt
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As one fruitful example, the design, synthesis, and evaluation of MMP
inhibitors were studied with N-aryl sulfonyl homocysteine hydroxamate inhibitors
(Table 1.4).41The data showed that hydrophobic aryl groups significantly
influenced potency. The dipyridyl methyl amide analogue Fe displayed similar
potency to the monopyridyl analogue Fb while the additional cyclohexyl analogue
Ff lost potent activity compared to the single cyclohexyl analogue Fc. On the
other hand, both monopyridyl Fb and dipyridyl Fe analogues displayed greater
than 20-fold selectivity against MMP2, MMP3, MMP9, and MMP13 compared to
MMP1. The polarity of the pyridyl derivatives containing nitrogen might be a
significant factor for MMP selectivity.
As another representative example, MMP pyridyl derivatives enhanced
biological inhibitory activity (Table 1.5). Compounds Ha, Hb, and Jb displayed
poor potency, while inactivity was observed in compounds Hc, I, and Ja. On the
other hand, the pyridyl group on compound Jb lead to great potency with the
selective inhibitory activity for MMP9 (IC50 83 nM) against MMP1 (IC50 15000
nM). The aliphatic substituents on compound Ha and Hb lead to greater inhibitory
activity compared to analogues with the hydrophilic sustituents (Hc, I, and Ja ).
Despite the hydrophilicity of pyridyl group, the favorable interaction of the pyridyl
derivative with MM9 specified that the nitrogen atom may impart selectivity.
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Table 1.5. Collagenase 1 (MMP1), gelatinase-A (MMP2), stromelysin 1 (MMP3), gelatinase-B
(MMP9), collagenase 3 (MMP13) inhibition by N-arylsulfonylaziridine hydroxamic acid analogues

Compounds
MMP1

MMP2

IC50, nM
MMP3

MMP9

MMP13

G

104

0.7

0.7

2.5

12

Ha
Hb

>10 000
26 400

617
259

213
595

184
203

380
231

Hc
I

>100 000
56 000

15 000
98 000

10 000
>100 000

4 770
>100 000

8 775
>100 000

Ja

50 000

3 600

2 000

500

>100 000

Jb

15 000

237

164

83

300

1.13 Evaluation of a pyridyl substituent on an HDAC inhibitor, Largazole
As the most recent example of the enhanced biological activity of an
HDAC inhibitor containing nitrogen, natural product largazole analogues were
reported with significant bioactivity (Figure 1.10).42 Largazole was isolated from a
marine cyanobacterium of the genus Symploca and showed selective activity
against transformed human mammary epithelial cells (MDA-MB-231, GI50 7.7
nM) over nontransformed murine mammary epithelial cells (NMuMG, GI50 122
nM).43 Also, the selectivity was displayed against transformed fibroblastic
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osteosarcoma cells (U2OS, GI50 55 nM) over nontransformed fibroblasts
(NIH3T3, GI50 480 nM). Analogues Ka and Kb showed significantly increased
inhibitory activities for HDAC1 over HDAC6 (80%) while the parent compound
(largazole) and analogue Kc displayed modest selective inhibition. Investigation
of potential selective inhibitors has been an attractive target for chemists and
biologists since specific isoforms might offer opportunities to develop selective
anti-cancer drugs. With the biological activity trend, a compound containing a
pyridyl group was synthesized, screened, and discussed in our research
(Chapter 4).

Figure 1.10. Structures of largazole and analogues
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Currently, SAHA and the other candidates inhibit multiple HDAC
members. However, isoform-specific HDAC inhibitors are promising targets with
respect to clinical efficacy due to the fact that broad-spectrum inhibitors have
demonstrated toxicities in the clinic.44 The mechanism of relative action between
the selectivity and toxicity of HDAC inhibitors in the clinic is not well-defined, but
might reveal new mechanism-based therapeutics for cancers. Therefore, several
studies have reported a link among different HDAC family members, specific
tumor characteristics, and reduced toxicity profiles.45 Specifically, HDAC inhibitor
cytotoxicities of pediatric acute myeloid leukemia (AML) cell lines were tested by
using

MTT

(3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenylterazolium-bromide)

assays.45e At clinically practicable concentrations, dual HDAC inhibitors that
inhibited both HDAC1 and HDAC6 displayed the best anti-leukemic activities in
the four pediatric AML cell lines (THP-1, CMS, Kasumi-1, and MV4-11). As
mentioned earlier, pre-clinical evaluation of HDAC6-selective inhibitors was
highlighted in cardiovascular disease.35 Furthermore, investigating HDAC
inhibitors with hydrophilic substituents including a pyridyl group might enhance
selective inhibition compared to common pan inhibitors. Even though the function
or regulation of individual HDAC proteins is still not clear, the development of the
specific-isoform HDAC protein inhibitors will lead optimal drugs for a variety of
specific diseases.
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CHAPTER 2 – SYNTHESIS OF SAHA ANALOGUES MODIFIED AT THE C3
POSITION

2.1

Rationale for design of the SAHA analogues containing substituents
on the C3 position
Inhibitor binding to a zinc atom at the bottom of the active site plays a

critical role in potency. Therefore, introducing substituents near hydroxamic acid
would help understand structural requirements of HDAC inhibitors. The SAR
study of SAHA on the linker area is relatively unexplored, in spite of it is being a
fruitful potential area (Chapter 1.5). Especially, there is the possibility to develop
isoform selective inhibitors through designing a library of SAHA analogues on the
linker. When SAHA is present in HDAC active site, it has been observed that the
linker is tightly surrounded by a hydrophobic tunnel (Figure 1.4). We theorized
that hydrophobic substituents attached at the linker would display better
interaction with the HDAC active site than hydrophilic substituents.
To explore the impact of substituents in the liker area, we previously
studied SAHA analogues with hydrophobic substituents attached on the C2
position (Figure 2.1).26 In this case, inhibitor potency was significantly reduced
regardless of substituent size. The lack of potency of the C2-SAHA analogues
indicates that limited flexibility exists in the HDAC active site near the hydroxamic
acid group. In

Figure 2.1. Structures of SAHA analogues containing substituents on the
C2 and C3 position

contrast,

high

potency

(nM

range)

HDAC
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inhibitors have been created with bulky substituent near the solvent-exposed
region.27c,

31, 46

Therefore, we proposed that HDAC proteins would be more

tolerant of SAHA analogues containing substituents positioned closer to the
solvent exposed surface.
To systematically probe the impact of substituents present in the linker,
SAHA analogues with substituents on the C3 position were synthesized (Figure
2.1).47 We theorized that analogues with substituents attached at the C3 position
would display more potent inhibition compared to analogues with C2 substituents
due to their location closer to the solvent-exposed region.

2.2

Initial synthesis
We initially synthesized the C3-SAHA n-butyl analogue 1a, as shown

Scheme 1. The ring of commercially available ε-caprolactone 2 was opened with
aniline and trimethyl aluminum to give alcohol 3, which was subjected to Swern
oxidation to give aldehyde 4. The Horner-Wadsworth-Emmons reaction with
trimethyl phosphonoacetate gave the corresponding α,β-unsturated ester 5. The
(E) and (Z)-isomers of ester 5 were separated by column chromatography and
then individually treated with a copper (I) bromide dimethylsulfide complex to give
the n-butyl ester 6a. Saponification of 6a gave carboxylic acid 7, which was
coupled with O-benzyl-protected hydroxamine. O-benzyl-protected hydroxamic
acid 8 was deprotected by hydrogenolysis to give the C3-n-butyl SAHA 1a.
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Scheme 2.1. Initial synthesis of C3-SAHA analogue (n-butyl derivative 1a)

2.3

Optimized synthesis
To create the remaining C3-SAHA analogues, several aspects of the

synthesis were improved (Scheme 2.2).

Scheme 2.2. Optimized synthesis of C3-SAHA analogues 1d -1e
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First, the 1,4-conjugate addition reaction (5 to 6) was performed using a
mixture of (E) and (Z) isomers without the separation. Second, we found that
when preparing compound 6e from methyl lithium, no addition product was
observed. However, addition of trimethylsilane chloride (TMSCl) to the reaction
gave excellent yield.48 With this success, TMSCl was included in the addition
reaction with all remaining analogues. Finally, we used a direct, one-step
conversion of ester 6 to the final product 1. In the synthesis of C3-n-butyl SAHA
1a, a benzyl-protected hydroxamic acid intermediate 8 was used en route to the
hydroxamic acid final product, as previously reported (Scheme 1).26 However,
40% yield after three steps (saponification, coupling O-benzyl hydroxylamine,
and benzyl deprotection) was unsatisfying. The direct conversion using
neutralized hydroxylamine in methanol was more efficient compared to the threestep conversion and was employed for all remaining analogues (1b-1e). Using
theses modified conditions, the phenyl, ethyl, vinyl, and methyl analogues 1b-1e
were synthesized (Scheme 2.2).

2.4

Biological analysis
The inhibitory activities of the C3-SAHA were measured using Fluor de

Lys™ in vitro fluorescence activity assay kit (Biomol) using HeLA cell lysates as
the source of HDAC activity by Dr. Sujith Weerasinghe (Table 2.1).26
The methyl variant 1e was the most potent analogue, displaying an IC50 of
350 nM, which is only 4-fold less potent than SAHA (90 nM). Theses results
indicate that the active site of HDAC proteins can accommodate a small methyl
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substituent at the C3 position. The potency of the remaining analogues
decreased with increasing size of the C3 substituent. The n-butyl and phenyl
analogues (1a and 1b) displayed the weakest inhibitory activity (184 µM and 73
µM, respectively). Interestingly, the ethyl-substituted analogue 1c displayed 91fold decreased activity compared to the methyl analogue 1e, despite containing
only one additional methylene. Likewise, the vinyl analogue 1d showed
significantly reduce activity compared to the methyl analogue 1e. In total, the
data indicated that a C3-methyl substituted SAHA analogue maintains nM
potency, but substituents larger than methyl result in a reduction in potency.

Table 2.1. HDAC inhibition by SAHA, MS-275, and the C3-SAHA analogues using HeLa cell
lysates
Compounds
R
IC50, Mª
SAHA

0.090  0.004

MS-275

3.2  0.1

1a

n-Butyl

184  14

1b

Phenyl

73  14

1c

Ethyl

32  4

1d

Vinyl

15  1

1e

Methyl

0.350  0.05

ªValues are the mean of three experiments with standard error given.

The inhibition results are consistent with the hypothesis that linker
substituents are accommodated in the HDAC active site when positioned closer
to the solvent exposed capping group of SAHA. While the C3-methyl analogue
displayed potency comparable to SAHA (4-fold reduced), the previously reported
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C2-methyl analogue (IC50 of 134 µM) displayed 1488-fold reduced activity versus
SAHA.26 Interestingly, the C3-n-butyl variant 1a is less potent (184 µM IC50) than
the previously reported C2-n-butyl analogue (72 µM IC50),26 suggesting that the
area of the HDAC active site near the C2 and C3 linker position displays
structural differences.
We next tested the isoform selectivity of the C3-SAHA analogues.
Creating isoform selective HDAC inhibitors has been challenging. 20 However, the
availability of selective inhibitors would provide powerful chemical tools to dissect
the individual functions of the HDAC isoforms, in addition to providing lead
antitumor drug candidates. To assess the isoform selectivity of the C3-SAHA
analogues, HDAC1 and HDAC3 representing class I and HDAC6 representing
class II were tested at a single concentration near to their IC 50 values using the
Fluor de Lys™ kit (Figure 2.2). As expected, SAHA almost equally inhibited
HDAC1, HDAC3, and HDAC6.30 In contrast, the ethyl variant 1c showed greater
potency for HDAC6 over HDAC1 and HDAC3 at 32 µM. The butyl, phenyl, and
vinyl variants (1a, 1b, and 1c) also showed similar, although more modest,
preference for HDAC6 over HDAC3.

30

100

Deacetylase activity Percentage (%)

HDAC1
HDAC3
HDAC6

80

60

40

20

0

SAHA

1a
n-butyl

1b
phenyl

1c
ethyl

1d
vinyl

1e
methyl

Figure 2.2. Screen of C3-SAHA analogues against HDAC1, HDAC3, and HDAC6 with
125 nM SAHA, 32 µM 1a-d, and 375 nM 1e.

To more rigorously assess the selectivity observed in the initial screen, we
determined the IC50 values of the C3-ethyl variant 1c because it displayed the
most promising results in the initial screen. The C3-ethyl analogue 1c displayed
12-fold selectivity for HDAC6 over HDAC3 and 3-fold selectivity for HDAC6 over
HDAC1 (Table 2.2). In addition, it displayed selectivity within class I, with 4-fold
preference for HDAC1 over HDAC3. As a control, SAHA displayed similar
inhibitor activity against the isoform, as expected (Table 2.2).30 The isoform
selectivity analysis shows that a substituent on the C3 position can transform
SAHA from non-selective inhibitor to an HDAC6-selective one. As a comparison,
the HDAC6-selective inhibitor tubacin displays 7-fold selectivity for HDAC6 over
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HDAC149 and has been used widely in cell biology studies. 50 Therefore, the data
indicate that isoform selective SAHA analogues can be generated by attaching a
substituent to the linker chain.

Table 2.2. IC50 values of SAHA and the C3-ethyl SAHA variant 1c for HDAC1, HDAC3, and
HDAC6
a

Compound

IC50/µM
HDAC1

SAHA
1c

0.096 ±

0.016

22 ± 2

HDAC3
0.146 ± 0.012
97 ± 6

HDAC6
0.074 ±

0.009

8±1

SAHA analogues with substituents on the C3 position displayed HDAC6selective inhibition, in contrast to the broad-spectrum inhibitor SAHA. These
results reveal that small structural changes in the linker region of SAHA can
significantly influence selectivity.

2.5

Experimentals

2.5.1 General methods
Starting materials, reagents, and solvents for reactions obtained from
Acros, Sigma-Aldrich, and VWR were used as purchased. Moisture-sensitive
reactions were performed under argon with dried glassware and dry solvent.
Iron-sensitive reactions were performed with acid-washed glassware and were
purified with silica gel that was washed with 6M aqueous hydrochloric acid
through at least 3 times. Thin-layer chromatography with 60Å, 250µm Partisil®
K6F fluorescent indicator plates was used to monitor reactions.

Flash
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chromatography was performed with 60 Å, 230-400 mesh silica gel (Whatman).
Solvents were removed by rotary evaporation (Büchi Rotavapor R-114 and Büchi
Waterbath B-480) and a vacuum pump (Welch Vaccum, Thomas Industries,
Inc.). NMR spectra were recorded in CDCl3 or CD3OD using a Varian Unity 300
MHz or Varian L900 400 MHz.

Mass spectrometric analysis was performed at

Wayne State University’s Central Instrumentation facility using a Waters LCT
Premier XE ESI-LC-MS TOF or a Waters GCT EI-TOF.

IR spectra were

recorded in Jasco FT/IR – 4100. HPLC analysis was performed with a Waters
1525 Binary HPLC pump, Waters 2998 Photodiode Array detector, and a
Symmetry® Reverse Phase C18 5µm column (4.6x150 mm Diameter) using a
gradient of 10% Buffer A to 90% Buffer B over 20 min (Buffer A = water with
0.1% TFA; Buffer B = HPLC grade acetonitrile) at 1.0 mL/min at room
temperature.
2.5.2 Experimental Procedures and Compound Characterization

5-Hydroxy-N-phenylpentanamide (3). Trimethyl aluminum (1.88 mL, 3.75
mmol) and aniline (0.34 mL, 3.75 mmol) were stepwise added to a solution of ε–
caprolactone (0.28 mL, 2.5 mmol) in dry THF (25 mL) at 0ºC. The mixture was
stirred and warmed to room temperature over 3 h. The reaction mixture was
quenched by a dropwise addition of 1.0 M aqueous hydrochloric acid until
evolution of gas was not observed. The mixture was subsequently diluted with
anhydrous diethyl ether (10 mL) and washed with distilled water (5 mL). The
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aqueous layer was extracted with diethyl ether (10 mL) at least 3 times. The
organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The
residue was purified by column chromatography (20% acetone/CH2Cl2) on silica
gel to give 3 (469 mg, 91%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.41 (m, 2H),
1.58 (m, 2H), 1.71 (m, 2H), 2.39 (bs, 1H), 2.60 (m, 2H), 3.59 (m, 2H), 7.10 (t,
1H), 7.29 (t, 2H), 7.59 (d, 2H), 7.90 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORMD): 25.8, 25.9, 32.1, 39.1, 61.9, 120.2, 124.1, 128.9, 138.8, 173.5; IR: 3298,
3136, 3063, 2936, 2863, 1663, 1599, 1544, 1498, 1442, 1309, 908, 730 cm -1;
HRMS ( EI-TOF, m/z): found [M] 207.1259, calc. for C12H17NO2, 207.1259.

6-Oxo-6-(phenylamino)hexanal (4). To a solution of DMSO (1.75 mL, 24.62
mmol) in CH2Cl2 (75 mL) was added oxalyl chloride (5.60 mL, 11.19 mmol)
dropwise and then 5-hydroxy-N-phenylpentanamide 3 (1.55 g, 7.46 mmol)
stepwise at -78ºC. The reaction mixture was stirred for 45 min before
triethylamine (TEA, 7.05 mL, 50.73 mmol) was added dropwise at -78 ºC. The
mixture was warmed to room temperature and stirred for an additional 1 h. The
reaction mixture was quenched by adding distilled water (75 mL). The mixture
was diluted with CH2Cl2 (25mL) and washed with 1.0 M aqueous hydrochloric
acid (25 mL), an aqueous solution of saturated NaHCO3 (100 mL), and brine (100
mL). The organic layer was dried over anhydrous Na2SO4, filtered, and
concentrated.

The

residue

was

purified

by

column

chromatography

(ether:petroleum ether 4:1) on silica gel to give 4 (1.25 g, 81%). 1H-NMR (δ, ppm,
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CHLOROFORM-D): 1.67-1.72 (m, 4H), 2.36 (t, 2H), 2.47 (t, 2H), 7.07 (t, 1H),
7.28 (t, 2H), 7.52 (d, 2H), 9.74 (bs, 1H);

13

C-NMR (δ, ppm, CHLOROFORM-D):

21.7, 25.1, 37.4, 43.8, 120.2, 124.5, 129.2, 138.2, 171.3, 202.7; IR: 3305, 3198,
3140, 3059, 2940, 2866, 2826, 2726, 1721, 1664, 1599, 1543, 1498, 1442, 1310,
909, 730 cm-1; HRMS (EI-TOF, m/z): found [M] 205.1106, calc. for C12H15NO2,
205.1103.

8-Oxo-8-(phenylamino)-oct-2-enoate (5). To a solution of NaH (435 mg, 10.88
mmol) in THF (64 mL) was added trimethyl phosphonoacetate (1.6 mL, 10.88
mmol) dropwise at 0 ºC and the mixture was stirred for 15 min. To the solution
was added 6-oxo-6-(phenylamino)hexanal 4 (1.3 g, 6.40 mmol) at -78 ºC and the
mixture was stirred for 15 min. The mixture was allowed to warm to room
temperature and stirred for an additional 1 h. The mixture was quenched by
addition of an aqueous solution of saturated NH4Cl until evolution of gas was not
observed. The mixture was washed with distilled H2O (64 mL) at least 3 times.
The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated.
The residue was purified by column chromatography (ether:petroleum ether 2:3)
on silica gel to give 5 (E-isomer; 1,136 mg, 68%, Z-isomer; 289mg, 17%).

For

preparation of butyl derivative 6a, the E and Z isomers were used separately, as
described below.

For the other derivatives 6b-e, the E isomer alone or a

mixture of E/Z isomers was used. Synthesis of the mixture of E/Z isomers was
similar that of each isomer, except the following reagents were used:

trimethyl
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phosphonoacetate (391 mL, 2.57 mmol) in THF (15 mL), NaH (102 mg, 4.27
mmol) and 6-oxo-6-(phenylamino)hexanal 4 (310 mg, 1.51 mmol). The residue
was purified by column chromatography (ether:petroleum ether 2:3) on silica gel
to give 5 (E+Z) (391 mg, 99%).

(Z)-isomer 1H-NMR (δ, ppm, CHLOROFORM-

D): 1.54 (m, 2H), 1.76 (m, 2H), 2.38 (t, 2H), 2.68 (q, 2H), 3.71 (s, 3H), 5.79 (d,
1H, J=180 Hz), 6.24 (m, 1H), 7.09 (t, 1H), 7.29 (m, 2H), 7.51 (d, 2H), 7.64 (s,
1H); (E)-isomer 1H-NMR (δ, ppm, CHLOROFORM-D): 1.54 (m, 2H), 1.76 (m,
2H), 2.21 (q, 2H), 2.38 (t, 2H), 3.71 (s, 3H), 5.82 (d, 1H, J=448 Hz), 6.94 (m, 1H),
7.08 (t, 1H) 7.27 (m, 2H), 7.49 (d, 2H); (E+Z)-isomer
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C-NMR (δ, ppm,

CHLOROFORM-D): 25.3, 27.8, 32.2, 37.5, 51.7, 120.1, 121.5, 124.3, 129.2,
138.2, 149.2, 150.4, 167.4, 171.3; IR: 3674, 3308, 2950, 1721, 1658, 1600,
1541, 1498, 1441, 1310, 910, 756, 693 cm-1; HRMS (EI-TOF, m/z): found [M]
261.1361, calc. for C15H19NO3, 261.1365.

8-Oxo-8-(phenylamino)-3-n-butyloctanoate (6a). To a solution of Cu(I)Br·SMe2
(880 mg, 4.28 mmol) in THF (14.3 mL) was added n-butyl lithium (5.35 mL, 8.56
mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The reaction
mixture was cooled to -78 ºC before addition of (Z)-8-oxo-8-(phenylamino)-oct-2enoate 5 (373 mg, 1.43 mmol, Z isomer only) at -78 ºC. The reaction was stirred
for 3 h at -78 ºC to room temperature and then quenched by addition of 1.0 M
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aqueous hydrochloric acid until a color of the mixture changed to blue (CuCl2(aq)).
The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated.
The residue was purified by column chromatography (ether:petroleum ether 2:3)
on silica gel to give 6a (378 mg, 83% from the Z isomer). The synthesis starting
from the E isomer of 5 was similar to that above except the following reagents
were used: Cu(I)Br·SMe2 (470 mg, 2.28 mmol) in THF (11 mL), n-butyl lithium
(2.85 mL, 4.56 mmol), and (E)-8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg,
0.76 mmol, E isomer only) at -78 ºC. Chromatography gave 6a (117 mg, 48%
from the E isomer). 1H-NMR (δ, ppm, CHLOROFORM-D): 0.87 (t, 3H), 1.24-1.32
(m, 10H), 1.70 (m, 2H), 1.84 (m, 1H), 2.21 (m, 2H), 2.33 (t, 2H), 3.65 (s, 3H),
7.07 (t, 1H), 7.29 (t, 2H), 7.51 (d, 2H), 7.62 (bs, 1H);
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C-NMR (δ, ppm,

CHLOROFORM-D): 14.3, 23.1, 25.9, 26.1, 29.0, 33.5, 33.7, 35.0, 37.7, 39.1,
51.7, 120.0, 124.3, 129.1, 138.3, 171.7, 174.4; IR: 3303, 3197, 3137, 3059,
2928, 2857, 1737, 1662, 1600, 1542, 1499, 1441, 1309, 903, 755, 693 cm-1;
HRMS (EI-TOF, m/z): found [M] 319.2143, calc. for C19H29NO3, 319.2147.

8-Oxo-8-(phenylamino)-3-phenyloctanoate (6b). To a solution of Cu(I)Br·SMe2
(945 mg, 4.59 mmol) in THF (7.7 mL) was added phenyl lithium (4.59 mL, 9.19
mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The reaction
mixture was cooled to -78 ºC. To the solution was added trimethylsilyl chloride
(TMSCl, 1.76 mL, 13.78 mmol) dropwise and then 8-oxo-8-(phenylamino)-oct-2-
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enoate 5 (200 mg, 0.77 mmol, only E isomer) stepwise at -78 ºC.

Only the E

isomer of 5 was used because the presence of the Z isomer complicated
purification. The mixture was stirred for 3 h at -78 ºC and then quenched by
addition of an aqueous solution of NH4Cl:NH4OH (1:1) until a color of the mixture
turned to blue ((NH3)4CuCl2(aq)). The mixture was washed with the aqueous
solution of NH4Cl:NH4OH (1:1) (7.7 mL). The organic layer was dried over
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by
column chromatography (ether:petroleum ether 1:1) on silica gel to give 6b (154
mg, 59%).

1

H-NMR (δ, ppm, CHLOROFORM-D): 1.22 (m, 2H), 1.62-1.68 (m,

4H), 2.23 (m, 2H), 2.59 (m, 2H), 3.07 (m, 1H), 3.57 (s, 3H), 7.06 (t, 1H), 7.19 (m,
3H), 7.29 (m, 4H), 7.47 (d, 2H), 7.53 (bs, 1H);
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C-NMR (δ, ppm,

CHLOROFORM-D): 25.6, 27.0, 35.8, 37.6, 41.8, 42.1, 51.8, 120.1, 124.4, 126.8,
127.6, 128.7, 129.1, 138.3, 144.0, 171.6, 173.2; IR: 3310, 3045, 2924, 2857,
1698, 1603, 1600, 1456, 1378, 1265, 910, 755, 735 cm-1. HRMS (EI-TOF, m/z):
found [M+Na] 362.1732, calc. for C21H25NO3Na, 362.1732;

8-Oxo-8-(phenylamino)-3-ethyloctanoate (6c). The synthesis was similar that
of 6b except the following reagents were used: Cu(I)Br·SMe2 (945 mg, 4.59
mmol) in THF (7.7 mL), ethyl lithium (5.41 mL, 9.19 mmol), TMSCl (1.76 mL,
13.78 mmol), and 8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 0.77 mmol, E
and Z mixture).

The product was purified by column chromatography

(ether:petroleum ether 1:1) on silica gel to give 6c (215 mg, 96%). 1H-NMR (δ,
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ppm, CHLOROFORM-D): 0.85 (t, 3H), 1.23-1.38 (m, 6H), 1.9 (m, 2H), 1.78 (m,
1H), 2.21 (m, 2H), 2.32 (t, 2H), 3.64 (s, 3H), 7.07 (t, 1H), 7.28 (t, 2H), 7.51 (d,
2H), 7.77 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 11.0, 25.9, 26.2, 26.5,
33.1, 36.5, 37.7, 38.7, 51.7, 120.1, 124.3, 129.1, 138.4, 171.8, 174.4; IR: 3675,
3308, 3198, 3139, 3061, 2960, 2934, 1734, 1665, 1601, 1543, 1499, 1442, 1309,
911, 756, 733 cm-1; HRMS (EI-TOF, m/z): found [M] 291.1830, calc. for
C17H25NO3, 291.1834.

8-Oxo-8-(phenylamino)-3-vinyloctanoate (6d). The synthesis was similar to
that of 6b except the following reagents were used: CuI

(875 mg, 4.59 mmol) in

THF (7.7 mL), vinyl magnesium bromide (6.56 mL, 4.59 mmol), TMSCl (1.76 mL,
13.78 mmol), and 8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 0.77 mmol,
only E isomer). Only the E isomer of 5 was used because the presence of the Z
isomer

complicated

purification.

The

product

was

purified

by

column

chromatography (ether:petroleum ether 1:1) on silica gel to give 6d (191 mg,
86%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.33 (m, 2H), 1.39 (m, 2H), 1.70 (m,
2H), 2.30-2.34 (m, 4H), 2.50 (m, 1H), 3.64 (s, 3H), 5.00 (m, 2H), 5.57 (m, 1H),
7.08 (t, 1H), 7.29 (t, 2H), 7.50 (d, 2H), 7.57 (bs, 1H);

13

C-NMR (δ, ppm,

CHLOROFORM-D): 25.6, 26.7, 34.1, 37.7, 40.1, 40.4, 51.7, 115.6, 120.0, 124.4,
129.2, 138.3, 140.9, 171.7, 173.3; IR: 3315, 3199, 3138, 3076, 2939, 2859,
1737, 1601, 1543, 1499, 1442, 1308, 915, 755 cm -1; HRMS (EI-TOF, m/z): found
[M] 312.1564, calc. for C17H23NO3Na, 312.1576.
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8-oxo-8-(phenylamino)-3-methyloctanoate (6e). The synthesis was similar that
of 6b except the following reagents were used: Cu(I)Br·SMe2 (945 mg, 4.59
mmol) in THF (7.7 mL), methyl lithium (5.74 mL, 9.19 mmol), TMSCl (1.76 mL,
13.78 mmol) and 8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 0.77 mmol, E
and Z mixture). The residue was purified by column chromatography
(ether:petroleum ether 2:3) on silica gel to give 6e (232 mg, 99%). 1H-NMR (δ,
ppm, CHLOROFORM-D): 0.92 (d, 3H), 1.21-1.40 (m, 4H), 1.72 (m, 2H), 1.95 (m,
1H), 2.11-2.36 (m, 4H), 3.66 (s, 3H), 7.09 (t, 1H), 7.31 (t, 2H), 7.51 (d, 2H), 7.68
(bs, 1H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 19.9, 25.8, 26.6, 30.3, 36.3,

37.7, 41.7, 51.7, 120.0, 124.3, 129.2, 138.3, 171.7, 174.1; IR: 3305, 3197, 3137,
3060, 2931, 2859, 1738, 1662, 1600, 1539, 1499, 1442, 1309, 1008, 902, 756
cm-1; HRMS (EI-TOF, m/z): found [M] 277.1678, calc. for C16H23NO3, 277.1678.

3-n-Butyl-N1-hydroxyl-N8-phenyloctanoic acid (7). To a solution of 8-oxo-8(phenylamino)-3-n-butyloctanoate 6a (492mg, 1.54mmol) was added NaOH
(6.16 mL, 30.79 mmol) in MeOH (15 mL) and the mixture was refluxed overnight.
The reaction was quenched by adding conc. aqueous hydrochloric acid (up to pH
6) and then extracting with H2O (5 mL) and ethyl acetate (20 mL). The organic
layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue
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was purified by column chromatography (20% acetone/CH2Cl2) on silica gel to
give 7 (189 mg, 40%). 1H-NMR (δ, ppm, CHLOROFORM-D): 0.87 (t, 3H), 1.271.37 (m, 10H), 1.63 (m, 2H), 1.86 (m, 1H), 2.17-2.36 (m, 4H), 7.09 (t, 1H), 7.30 (t,
2H), 7.50 (d, 2H), 7.71 (bs, 1H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 14.3,

23.1, 25.9, 26.1, 29.0, 33.5, 33.7, 35.0, 37.7, 39.1, 120.2, 124.5, 129.1, 138.2,
172.1, 179.5; IR: 3306, 3195, 3137, 3060, 2928, 2858, 1705, 1662, 1599, 1543,
1499, 1442, 1309, 907, 755, 692 cm-1; HRMS (EI-TOF, m/z): found [M] 305.1993,
calc. for C18H27NO3, 305.1991.

3-n-Butyl-N1-benzyloxy-N8-phenyloctanediamide (8). O-benzylhydroxylamine
hydrochloride salt (144g, 0.9mmol) and Na2CO3 (47g, 0.45mmol) were dissolved
in distill H2O (9 mL), extracted with diethyl ether (9 mL) and concentrated. TBTU
(289g, 0.9 mmol) and 3-n-butyl-N1-hydroxyl-N8-phenyloctanoic acid 7 (189mg,
0.6mmol) were added to the neutralized O-benzylhydroxylamine residue in
CH3CN (6mL). The reaction mixture was stirred overnight at room temperature
and then quenched by adding NaHCO3 (6 mL). The mixture was extracted with
H2O and DCM (1:1). The organic layer was dried over anhydrous Na2SO4,
filtered, and concentrated. The residue was purified by column chromatography
(10% acetone/DCM) on silica gel to give 8 (121 mg, 49%). 1H-NMR (δ, ppm,
CHLOROFORM-D): 0.86 (t, 3H), 1.22-1.35 (m, 12H), 1.66 (m, 1H), 1.94 (m, 2H),
2.30 (m, 2H), 5.29 (s, 2H), 7.07 (t, 1H), 7.28 (m, 7H), 7.55 (d, 2H), 8.12 (bs, 1H);
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13

C-NMR (δ, ppm, CHLOROFORM-D): 14.3, 23.1, 25.3, 25.7, 29.1, 32.5, 33.7,

35.0, 37.2, 37.9, 78.4, 120.1, 124.3, 128.8, 129.1, 129.4, 138.5, 171.0, 172.3; IR:
3724, 3195, 3140, 3064, 2929, 2858, 1656, 1620, 1600, 1544, 1498, 1442, 1380,
1309, 1253, 1046, 1030, 975,

911, 734, 695 cm-1; HRMS (EI-TOF, m/z): found

[M] 410.2566, calc. for C25H34N2O3, 410.2569.

3-n-Butyl-N1-hydroxyl-N8-phenyloctandiamide (1a). To a solution of 3-n-butylN1-benzyloxy-N8-phenyloctanediamide 8 (121 mg, 0.3 mmol) in methanol (3mL)
was added 20% Pd(OH)2/C (32 mg, 0.03 mmol) in an acid-washed 25mL roundbottom flask and the reaction mixture was purged with H2 (g) for 30 s. The reaction
solution was stirred under H2 (g) for 30 min and then filtered through a plug of
Celite with MeOH (9 mL). The filtrate was concentrated to give 1a (89 mg, 92%)
as a clear oil.

1

H-NMR (δ, ppm, METHANOL-D4): 0.88 (t, 3H), 1.28-1.39 (m,

10H), 1.68 (m, 2H), 1.86 (m, 1H), 2.02 (d, 2H), 2.37 (t, 2H), 7.07 (t, 1H), 7.28 (t,
2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4): 13.2, 22.8, 25.9, 28.6,
33.1, 33.2, 35.0, 36.7, 37.6, 120.1, 123.9, 128.6, 138.7, 171.4, 173.5; IR: 3384,
3044, 2929, 2858, 1640, 1600, 1546, 1499, 1468, 1309, 976, 903, 755, 693 cm-1;
HRMS (EI-TOF, m/z): found [M] 320.2108, calc. for C18H28N2O3, 320.2100; HPLC
analytical purity analysis: 92%.
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3-Phenyl-N1-hydroxyl-N8-phenyloctandiamide

(1b).

To

a

solution

of

NH2OH∙HCl (315 mg, 4.54 mmol) in methanol (4.5 mL) was added KOH (509 mg,
9.08 mmol) at 0 ˚C in an acid-washed 25mL round-bottom flask. After stirring
for 20 min, 8-oxo-8-(phenylamino)-3-phenyloctanoate (6b) (154 mg, 0.45 mmol)
was added and the mixture was stirred for 8 h at 0°C. The reaction mixture was
quenched by adding 1mL of distilled water and adjusting to pH 6 by adding
concentrated aqueous hydrochloric acid. The mixture was diluted with 30 mL of
ethyl acetate, and washed with distilled water. The organic layer was dried over
anhydrous Na2SO4, filtered and concentrated. The residue was purified by
column chromatography (10% methanol/CH2Cl2) on acid-washed silica gel to
give 1b (48 mg, 31%).

1

H NMR (δ, ppm, METHANOL-D4): 1.22 (m, 2H), 1.55-

1.73 (m, 4H), 2.25-2.43 (m, 4H), 3.09 (m, 1H), 7.06 (t, 1H), 7.12-7.29 (m, 7H),
7.47 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4): 25.6, 26.8, 35.4, 36.6, 40.2,
42.3, 120.1, 124.0, 126.4, 127.5, 128.3, 128.5, 138.6, 143.9, 170.1, 173.4; IR:
3256, 3030, 2932, 2860, 2559, 1646, 1600, 1545, 1499, 1468, 1442, 1420, 1372,
1310, 1253, 906, 758 cm-1; HRMS (EI-TOF, m/z): found [M] 340.1789, calc. for
C20H24N2O3, 340.1787; HPLC analytical purity analysis: 91%.
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3-Ethyl-N1-hydroxyl-N8-phenyloctandiamide (1c). A similar procedure to that
for 1b was used, except for the following reagents: NH2OH∙HCl (520 mg, 7.48
mmol) in methanol (7.4 mL), KOH (839 mg, 14.96 mmol), 8-oxo-8-(phenylamino)3-ethyloctanoate (6c) (218 mg, 0.75 mmol) and stirring for 4 h. In this case, the
product was purified by column chromatography (8 % methanol/CH2Cl2) on acidwashed silica gel to give 1c (130 mg, 60%).

1

H-NMR (δ, ppm, METHANOL-D4):

0.88 (t, 3H), 1.28-1.41 (m, 6H), 1.68 (m, 2H), 1.81 (m, 1H), 2.01 (m, 2H), 2.36 (t,
2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4):
9.8, 25.9, 32.6, 36.5, 36.7, 37.1, 120.1, 123.9, 128.6, 138.7, 171.4, 173.5; IR:
3857, 3404, 2935, 2862, 1649, 1600, 1544, 1501, 1469, 1311, 978, 904, 758,
691 cm-1; HRMS (EI-TOF, m/z): found [M-H] 292.1718, calc. for C16H23N2O3,
292.1709; HPLC analytical purity analysis: 99%.

3-Vinyl-N1-hydroxyl-N8-phenyloctandiamide (1d). A similar procedure to that
for 1b was used, except for the following reagents: NH2OH∙HCl (456 mg, 6.57
mmol) in methanol (6.6 mL), KOH (737 mg, 13.13 mmol), 8-oxo-8-(phenylamino)3-vinyloctanoate (6d) (190 mg, 0.66 mmol), and stirring for 6 h. In this case, the
product was purified by column chromatography (8 % methanol/CH2Cl2) on acidwashed silica gel to give 1d (83 mg, 43%).

1

H-NMR (δ, ppm, METHANOL-D4):

1.33-1.47 (m, 4H),1.70 (m, 2H), 2.08 (m, 2H), 2.35 (t, 2H), 2.50 (m, 1H), 5.00 (q,
2H), 5.58 (m, 1H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H);

13

C-NMR (δ, ppm,
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METHANOL-D4): 25.6, 26.5, 33.9, 36.6, 38.3, 40.8, 115.0, 120.1, 124.0, 128.6,
138.7, 140.7, 170.3, 173.4; IR: 3299, 3079, 2931, 1647, 1600, 1542, 1500, 1442,
1312, 920, 758, 692 cm-1; HRMS (EI-TOF, m/z): found [M+Na] 313.1533, calc.
for C16H22N2O3Na, 313.1528; HPLC analytical purity analysis: 94%.

3-Methyl-N1-hydroxyl-N8-phenyloctandiamide (1e). A similar procedure to that
for 1b was used, except for the following reagents: NH2OH∙HCl (533 mg, 7.67
mmol) in methanol (7.7 mL), KOH (860 mg, 15.33 mmol), 8-oxo-8-(phenylamino)3-methyloctanoate (6e) (213 mg, 0.77 mmol), and stirring for 2 h. In this case, the
product was purified by column chromatography (10 % methanol/CH2Cl2) on
acid-washed silica gel to give 1e (160 mg, 75%). 1H-NMR (δ, ppm, METHANOLD4): 0.93 (d, 3H), 1.28 (m, 2H), 1.40 (m, 2H), 1.68 (m, 2H), 1.89 (m, 2H), 2.07
(m, 1H), 2.36 (t, 2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H); 13C-NMR (δ, ppm,
METHANOL-D4): 18.6, 25.8, 26.4, 30.4, 36.2, 36.7, 40.1, 120.1, 123.9, 128.6,
138.7, 171.1, 173.4; IR: 3198, 2927, 2855, 2359, 1657, 1598, 1544, 1499, 1443,
755, 691 cm-1; HRMS (EI-TOF, m/z): found [M] 278.1635, calc. for C15H22N2O3,
278.1630; HPLC analytical purity analysis: 98%.
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2.6

HDAC high-throughput assay

2.6.1 Fluorescence activity assay for libraries of SAHA analogues
A number of HDAC inhibitors have been attractive targets as
chemotherapeutic drugs due to that the overexpression activity of HDAC, which
leads malignant diseases, as discussed (Section 1.2). Our research is also
focused on development of novel HDAC inhibitors based on SAHA. Therefore,
SAHA analogues were screened compared to SAHA using a Fluorescence highthroughput assay. The deacetylase activity was measured using the Fluor de
Lys® activity assay (Enzo) using the manufacturer’s protocol(Figure 2.3).51

HDAC

Substrate

Developer (trypsin)

Figure 2.3. HDAC Fluorescent activity assay. Deacetylation of the substrate sensitizes to the
developer.

To measure global HDAC inhibition, HeLa lysates, which contains a
mixture of HDAC1-8 and HDAC10-11, were incubated with or without SAHA
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analogues in HDAC assay buffer solution. After the initial incubation, Fluor de
Lys® substrate in HDAC assay buffer was added to the reaction. The peptidic
substrates consisted of an ε-acetylated lysine residue and a 4-methylcoumarin-7amide at the carboxy terminal unit. In the reaction catalyzed by HDACs, the
acetylated lysine residue of the substrate was deacetylated, while acetylated
lysine would remain in the reaction when inhibited by the SAHA analogues. To
quench the reaction and allow color development, Fluor de Lys® developer was
added to the reaction mixture. In this reaction, the only deacetylated peptidic
lysine substrates containing the methylcoumarinamide were cleaved by trypsin to
release the fluorescence molecule, methylcoumarin. In other word, the acetylated
lysine substrate present when the reaction was inhibited by the SAHA analogues
did not result in measurable cleavage by trypsin and did not release the
fluorescence molecule (no fluorescence activity). As a result, the high level of
deacetylated activity of the substrates indicated low inhibitory activity of the
SAHA analogues. The fluorescence intensity was determined using a Geniosplus
Fluorimeter (Tecan) with excitation at 360 nm and emission at 465 nm.

2.6.2 HDAC assay procedure
HDAC activity of the C3-SAHA analogues was measured using the Fluor
de Lys™ activity assay (Biomol) using the manufacturer’s protocol by Dr. Sujith
Weerasinghe. To measure global HDAC inhibition, HeLa lysates (approximately
4µg of total protein) were incubated with small molecule inhibitor or without small
molecule inhibitor (2% DMSO) in HDAC assay buffer (50 mM Tris/Cl, pH 8.0, 137
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mM NaCl, 2.7 mM KCl, 1 mM MgCl2) at a final volume of 25 µL for 30 min at 30
˚C with shaking.

Concentrations of small molecule between 1 nM and 1 mM

final concentration were used to determine IC50 values.

Because the small

molecules were stored in DMSO, dilution with HDAC buffer ensured that a
maximum of 2% DMSO was present in the final reaction mixture. After the initial
incubation, Fluor de Lys™ substrate in HDAC assay buffer (100 µM final
concentration) was added to make a total reaction volume of 50µL. The reaction
mixture was incubated at 30˚C for 45 min with shaking. To quench the reaction
and allow color development, Fluor de Lys™ developer (2.5 µL of 20X diluted up
to

50 µL in HDAC assay buffer ) was added to give a final 100 µL volume and

incubated with shaking for 5 min at room temperature. The fluorescence intensity
was determined using a Geniosplus Fluorimeter (Tecan) with excitation at 360
nm and emission at 465 nm.
To perform the isoform selectivity studies, the procedure was similar
except that the HeLa cell lysates were replaced with 0.2 µg HDAC1 (specific
activity = 42.5 pmol/min/µg), 0.05 µg HDAC3 (specific activity = 249 pmol/min/µg)
or 0.25 µg HDAC6 (specific activity = 257 pmol/min/µg), purchased from BPS
Biosciences.

In addition, the Fluor de Lys™ substrate was used at a final

concentration of 50 µM for HDAC1 or 25µM for HDAC3 and HDAC6.
For each trial, a no enzyme control sample was used to assess the
background. The background-corrected fluorescence units of small moleculetreated samples were then compared to that of untreated samples (set to 100%)
to give a percentage deacetylase activity. IC50 values were obtained by plotting

48
the percentage deacetylase activity versus the small molecule concentration and
fitting the data to a sigmoidal dose-response curve (y=100/(1+(x/m3)m4) using
KaleidaGraph software where m1 is the IC50 value in Molar units.

All

experiments were performed in triplicate with the mean and standard error
reported in the tables and figures.
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CHAPTER 3 – SYNTHESIS OF SAHA ANALOGUES MODIFIED AT THE C6
POSITION

3.1

Rationale for design of SAHA analogues modified at the C6 position
A limited number of structure activity relationship (SAR) studies on the

linker area of SAHA have been performed, even though the linker region might
influence inhibitory activity and selectivity (Section 1.7). In fact, many number of
inhibitors that have substituents on the linker have been discovered with great
potency and selective inhibition when substituents were attached near or on the
capping group (Section 1.9). Specifically, tubacin with a bulky substituent at the
capping group has been used in pharmacokinetic and clinical studies (Figure
1.9). Also, based on data from previous C2 and C3-SAHA libraries26,

47

,

substituents on the C6 position might lead to potent inhibitory activities because
C6-SAHA substituents would be located close to the solvent-exposed region of
the active site. As discussed in the chapter 2, the C3-SAHA ethyl analogue
showed selective inhibition for HDAC6 over HDAC1 and HDAC3.47 To expand
our understanding of the impact of substituents, synthesis of C6-SAHA
analogues with hydrophobic substituents was achieved because the carbon
linker is surrounded by a hydrophobic tunnel.
The earlier results from the C2 and
C3-SAHA libraries showed that the steric
environment on the SAHA carbon linker
Figure 3.1. Structure of SAHA analogues
containing substituents on the C6 position

caused reduced inhibitory activity, in
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addition to influencing selective inhibition.26,
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With the potential to improve

selectivity, the C6-SAHA library (Figure 3.1) was synthesized. We proposed that
the HDAC protein active site would not only be more tolerant of bulkier
substituents on the C6 position near the solvent-exposed area but the C6-SAHA
analogues would also display more selectivity compared to the C2 and C3-SAHA
analogues based on the previous reports about several class-selective inhibitors
with bulky substituents in the capping group region (Section 1.9).20

3.2

Initial synthesis
To elucidate the impact of substituents present near the solvent-exposed

area, C6-SAHA analogues were synthesized. Like C2 and C3-SAHA analogues
(Chapter 1 and 2), we selected hydrophobic substituents since the carbon linker
is surrounded by a hydrophobic tunnel (Figure 1.4). Also, we theorized that bulky
analogues on the C6 position would display more potent inhibition compared to
C2 and C3-SAHA analogues due to their proximity to the solvent-exposed
surface.
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Scheme 3.1. Initial synthesis of C6-SAHA analogue (methyl derivative 14a)

Initially, we synthesized the C6-SAHA methyl analogue 14a, as outlined in
Scheme 3.1. Due to symmetry compared to the C3-SAHA analogues, synthesis
of the C6-SAHA analogues was straightforward and similar to that of the C3SAHA library. The major differences between two syntheses are the following.
Commercially available ε-caprolactone 2 was opened to give methyl 6hydrohexanoate 9 under Fisher conditions instead of building the anilide
derivative. The alcohol compound 9 was subjected to Swern oxidation to give
aldehyde 10 similar to the C3-aldehyde formation. For the Horner-WadsworthEmmons reaction, using benzyl dimethyl phosphonoacetate instead of using
trimethyl phosphonoacetate gave the corresponding α,β-unsturated benzyl ester
11 that allowed incorporation of substituents, which provided the precursor for
anilide derivative 13a. A mixture of (E) and (Z)-isomers of ester 11 were treated
with a copper (I) iodide to give the methyl substituted ester 12a. Similar to the
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previous optimized synthesis of the C3-methyl SAHA analogue (Scheme 2)
where the 1,4-addition demonstrated quantitative yield, the C6-methyl ester 12a
was synthesized and characterized without impurities according to thin layer
chromatography (TLC) and 1H &

13

C NMR spectra analysis. Therefore, the

methyl ester 12a without purification was deprotected by hydrogenolysis and
coupled with aniline in 53% yield (over the three steps). In contrast to the C3SAHA library where the anilide derivative was installed at the beginning stage,
the anilide 13a was created from benzyl ester 12a at a late stage, which attached
substituents near the capping group. The methyl ester derivative 13a was directly
converted to the methyl hydroxamic acid 14a.

3.3

Modified synthesis

Scheme 3.2. Modified synthesis of C6-SAHA analogue 14b - 14d

To create the remaining C6-SAHA analogues, first, purification by column
chromatography was required after 1,4-addition since the mixture of (E) and (Z)
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isomers 11 were unable to completely react to produce phenyl ester 12b, as was
observed with the methyl derivative 12a (Scheme 3.2). Using the additional
purification step after the 1,4-addition, the t-butyl ester 12c, 2-ethylhexyl ester
12d, and isopropyl ester 12e were synthesized. The rest of syntheses for
hydrogenolysis, coupling, and conversion to hydroxamic acid were similar to the
methyl analogue synthesis. However, despite the purification, there was still
remaining unsaturated ester 11 after 1, 4-addition for obtaining phenyl ester 12b
due to the similar polarity. The mixture of unsaturated ester 11 and phenyl ester
12b were subjected to hydrogenolysis and coupling to give anilide 13b and
unsaturated anilide compound 13b´. Fortunately, 14b was completely purified
after conversion to hydroxamic acid in 60% yield (over the four steps).

3.4

Biological analysis
The HDAC inhibitory activities of the C6-SAHA library were measured

using the Fluor de Lys® in vitro fluorescence activity assay kit (Enzo). Unlike the
C3-SAHA library, the C6-SAHA analogue biological activities were performed by
Sun Ea Choi. The activities of the C6-SAHA compounds are summarized in
Table 3.1. Interestingly, the planar phenyl variant 14b was the most potent
analogue displaying an IC50 of 344 nM similar to the C3-methyl variant 1e (IC50 of
350 nM) and comparable to SAHA (4-fold reduced), IC50 of 86 nM. This is in
contrast to the C3-phenyl variant 1b (IC50 of 73000 nM), which displayed 811-fold
reduced activity versus SAHA.53 In addition, the smallest C6-methyl variant 14a
(IC50 of 349 nM) displayed similar potency to the phenyl variant. These results
indicate that the active site of HDAC proteins can accommodate a bulky
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substituent at the C6 position. Moreover, the longest analogues, the 2-ethylhexyl
variant 14d, still displayed potent inhibitory activity in the nM range. Likewise, the
bulkiest substituent with three methyl groups at the α-carbon, the t-butyl variant
14c, displayed only 20-fold reduced activity versus SAHA. In summary, the
inhibition data show that most C6-SAHA analogues maintain nM potency, but
substitution at the α-carbon decreases potent inhibitory activity.

Table 3.1. HDAC inhibition by SAHA, MS-275, and the C6-SAHA analogues using HeLa
cell lysates
Compounds
R
IC50, nMª
SAHA

86  4

MS-275

3200  100

14a

Methyl

349  20

14b

Phenyl

344  40

14c

t-Butyl

1940  300

14d

2-Ethylhexyl

456  30

ªValues are the mean of at least three experiments with standard error given.

These results are consistent with the hypothesis that the active site of
HDAC proteins accommodates large substituents near the solvent exposed area.
As expected, one trend for the C6-SAHA analogues is that the increasing size of
substituents has less influence on inhibitory activity compared to the C2 and C3SAHA analogues.
As mentioned earlier, the presence of methyl groups at the α-carbon
decreased inhibitory activity. We speculate that the t-butyl variant 14c might
display specific selectivity since the C3-ethyl variant 1c, which contains an α-
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methyl group, displayed selective inhibition for HDAC6 over HDAC1 and HDAC 3
and also showed significantly decreased inhibitory activity compared with the C3methyl variant 1e. To explore the role of an α-methyl group on selectivity,
synthesis of the isopropyl derivative would reveal the effect of α-carbon
substituents. Another possibility is that the hybridization at the α-carbon might
influence selectivity. For example, the C6-SAHA phenyl 14b and methyl variant
14a have sp2 and sp3 orbital structures. The data might provide key structural
information for binding site recognition. The long chain of the C6-SAHA 2-ethyl
hexyl analogue 14d might also affect isoform selectivity. To verify the influence of
sterics on isoform selectivity, testing the isoform selectivity of C6-SAHA
analogues is described. The results of the isoform selectivity of the C6-SAHA
analogues are outlined in Figure 3.2.
The isoform selectivity of C6-SAHA analogues was tested with HDAC1
and HDAC3 representing class I and HDAC6 representing class II. To assess the
isoform selectivity, all compounds were tested at a single concentration near to
their IC50 values using the Fluor de Lys® kit (Figure 3.2). As observed from
previous data, SAHA exhibited roughly equal inhibition against HDAC1, HDAC3,
and HDAC6. The phenyl variant 14b, which displayed the most potent inhibition
among the C6-SAHA analogues with HeLa cell lysates, similarly inhibited
HDAC1, HDAC3, and HDAC6 as well. In contrast, the methyl variant 14a showed
dual-preference for HDAC1 and HDAC3 over HDAC6 at 500 nM even though the
methyl 14a (IC50 of 349 nM) and phenyl variant 14b (IC50 of 344 nM) displayed
equal inhibition in the HeLa cell lysates. The difference between sp3 and sp2
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orbital structures might affect selectivity but not potency. The 2-ethylhexyl variant
14d with an additional carbon chain displayed selectivity for HDAC3 over HDAC1
and HDAC6 compared to the methyl variant 14a. Similar to the methyl variant
14a (IC50 of 349 nM), the 2-ethylhexyl variant 14d (IC50 of 456 nM) imparted
selectivity but not potency. However, the bulkiest analogue at the α–carbon
position, t-butyl variant 14c, displayed the opposite selectivity with preference for
HDAC1 and HDAC6 over HDAC3. In this case, the α-carbon substituent lead to
different interactions with each isoform HDAC active sites. The t-butyl substituent
encouraged dual-selectivity toward HDAC1 and HDAC6 over HDAC3, while the
inhibitory activity of t-butyl variant 14c (IC50 of 1.9 µM) showed 5-fold reduced
activity compared to the 2-ethylhexyl variant 14d (IC50 of 456 nM) and 20-fold
less potent than SAHA (IC50 of 86 nM). In summary, the data indicated that the
methyl, t-butyl, and 2-ethylhexyl variants (14a, 14c, and 14d) showed dissimilar
preference for each isoform HDAC proteins despite parallel potency. The
deacetylase activity of individual trial is summarized in Table C.5 in Appendix C.
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Figure 3.2. Initial screen of isoform selectivity of C6-SAHA analogues against
HDAC1, HDAC3, and HDAC6 with 125 nM SAHA, 500 nM 14a, b, d, and 2 µM 14c.

To more thoroughly assess the selectivity observed in the initial screen,
we determined the HDAC1, HDAC3, and HDAC6 IC50 values of the C6-t-butyl
variant 14c because it showed the most potential to create a dual-selective
inhibitor.

The C6-t-butyl analogue 14c displayed 6-fold greater potency for

HDAC1 over HDAC3 and 2-fold greater potency for HDAC6 over HDAC3 (Table
3.2). In addition, it displayed selectivity within class I for HDAC1 over HDAC3. As
a control, SAHA displayed non-selective inhibitor activity against the isoform, as
expected (Table 3.2).30 The selectivity analysis shows that a substituent on the
C6 position can influence the selectivity of SAHA from non-selective inhibitor to a
dual-selective HDAC1 and HDAC6 inhibitor. Furthermore, the C6-SAHA t-butyl
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analogue displays an IC50 value of 1.9 µM in the lowmicromolar range, while the
C3-SAHA

ethyl

analogue

(HDAC6-selective

inhibitor)

displayed

16-fold

decreasing potency (IC50 of 32 µM).47 Therefore, the data indicate that attaching
the t-butyl substituent to the linker chain on the C6 position may promote dualselective inhibition as well as potency on SAHA.

Table 3.2. IC50 values of SAHA and the C6-SAHA t-butyl variant 14c
for HDAC1, HDAC3, and HDAC6
Compound
IC50/µM
HDAC1

HDAC3

HDAC6

SAHA

0.096 ± 0.016

0.136 ± 11

0.074 ± 0.009

14c

0.993 ± 0.061

5.4 ± 0.7

2.4 ± 0.5

Specific

selective

HDAC

inhibitors

support

pathological

cardiac

remodeling studies. For example, a recent cardiac study reported that stressed
myocardium increased the catalytic activity of the class IIb HDAC, HDAC6.35
Moreover, the best anti-leukemic activities in the four pediatric AML cell lines
were observed by dual HDAC1 and HDAC6 inhibitors that inhibited both. 45e . The
function or regulation of dual-selective HDAC inhibitors is not well informed in
present even though dual-selective HDAC inhibitors might guide development of
prospective drugs of anti-diverse diseases.
From the initial isoform selectivity screen (Figure 3.2), SAHA analogues
with substituents on the C6 position displayed diverse selective inhibitions, such
as class I selectivity (methyl 14a), dual-class I, II selectivity (t-butyl 14c), and
isoform selectivity for HDAC3 (2-ethylhexyl 14d). Our results reveal that small

59
structural changes in the C6 position linker region of SAHA can significantly
influence selectivity with suitable potency.

3.5

Experimental

3.5.1 General methods
Additional details were shown in Section 2.5.1 of Chapter 2.
3.5.2 Experimental Procedures and Compound Characterization

Methyl 6-hydroxyhexanoate (9). Concentrated aqueous sulfuric acid (adjusted
to pH 6 using neutral pH meter paper (pH 1 to pH 14 range) as assessed with)
was dropwise added to a solution of ε–caprolactone (5.54 mL, 50 mmol) in
MeOH (50 mL). The mixture was stirred for 20 min. The mixture was
subsequently diluted with anhydrous diethyl ether (25 mL) and washed with
distilled water (equal volume to organic layer). The aqueous layer was extracted
with diethyl ether (equal volume to organic layer) at least 3 times. The combined
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated.
The residue was purified by column chromatography (12% acetone/CH2Cl2) on
silica gel to give 9 (7.23 g, 99%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.30 (m,
2H), 1.50 (m, 2H), 1.56 (m, 2H), 2.24 (m, 2H), 2.59 (bs, 1H), 3.52 (m, 2H), 3.58
(s, 3H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 24.8, 25.5, 32.4, 34.1, 51.8, 62.5,

174.5; IR: 3424, 2940, 2866, 1738, 1438, 1205, 857, 744 cm-1; HRMS ( EI-TOF,
m/z): found [M+Na] 169.0840, calc. for C7H14O3, 169.0841.
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1-Benzyl 8-methyl oct-2-enedioate (11). To a solution of DMSO (1.02 mL,
14.39 mmol) in CH2Cl2 (44 mL) was added 2 M oxalyl chloride in
dichloromethane (3.27 mL, 6.54 mmol) dropwise and then methyl 6hydroxyhexanoate 9 (0.638 g, 4.36 mmol) stepwise at -78ºC. The reaction
mixture was stirred for 45 min before triethylamine (TEA, 4.12 mL, 29.66 mmol)
was added dropwise at -78 ºC. The mixture was warmed
to room temperature and stirred for an additional 1 h. The
reaction mixture was quenched by adding distilled water
(44 mL). The mixture was washed with 1.0 M aqueous hydrochloric acid (44 mL),
an aqueous solution of saturated NaHCO3 (44 mL), and brine (44 mL). The
organic layer 10 was dried over anhydrous Na2SO4, filtered, and concentrated.
To a solution of NaH (0.513 g, 12.8 mmol) in THF (85 mL) was added
benzyl dimethyl phosphonoacetate (3.31 g, 12.8 mmol) dropwise at 0 ºC and the
mixture was stirred for 15 min. To the solution was added crude methyl 6oxohexanoate 10 (1.23 g, 8.55 mmol) at -78 ºC and the mixture was stirred for 15
min. The mixture was allowed to warm to room temperature and stirred for an
additional 1 h. The mixture was quenched by addition of an aqueous solution of
saturated NH4Cl until evolution of gas was not observed. The mixture was
washed with distilled H2O (85 mL). The organic layer was collected and the
aqueous layer was extracted with diethyl ether (equal volume to aqueous layer)
at least 3 times.

The combined organic layers were dried over anhydrous
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Na2SO4, filtered, and concentrated. The residue was purified by column
chromatography (diethyl ether: petroleum ether 1:6) on silica gel to give 11 (2.17
g, 92%).

(E+Z)-isomer 1H-NMR (δ, ppm, CHLOROFORM-D): 1.48 (m, 2H),

1.63 (m, 2H), 2.20 (q, 2H), 2.30 (t, 2H), 3.64 (s, 3H), 5.16 (s, 2H), 5.84 (d, 1H,
J=180 Hz), 6.98 (m, 1H), 7.35 (m, 5H);

13

C-NMR (δ, ppm, CHLOROFORM-D):

24.6, 27.6, 32.1, 33.9, 51.7, 66.2, 121.6, 128.3, 128.4, 128.8, 136.3, 149.5,
166.6, 174.0; IR: 3671, 2974, 1735, 1455, 1258, 1066, 907, 748, 698 cm-1;
HRMS (EI-TOF, m/z): found [M+Na] 299.1269, calc. for C16H20O4Na, 299.1259.

1-Benzyl 8-methyl 3-methyloctanedioate (12a). To a solution of Cu(I)I (1.06 g,
5.57 mmol) in THF (19 mL) was added 1.6M methyllithium in diethyl ether (6.97
mL, 11.15 mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The
reaction mixture was cooled to -78 ºC before addition of trimethylsilyl chloride
(TMSCl, 4.25 mL, 33.48 mmol). To the reaction mixture was dropwise added 1benzyl 8-methyl oct-2-enedioate 11 (513 mg, 1.86 mmol) at -78 ºC. The reaction
was stirred for 3 h at -78 ºC to room temperature and then quenched by addition
of 1.0 M aqueous hydrochloric acid until a color of the mixture changed to blue
(CuCl2(aq)). The organic layer was collected and the aqueous layer was extracted
with diethyl ether (equal volume to aqueous layer) at least 3 times. The combined
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. 1HNMR (δ, ppm, CHLOROFORM-D): 0.91 (d, 3H), 1.30 (m, 4H), 1.58 (m, 2H), 1.96
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(m, 1H), 2.19 (q, 1H), 2.32 (m, 3H), 3.65 (s, 3H), 5.10 (s, 2H), 7.34 (m, 5H); 13CNMR (δ, ppm, CHLOROFORM-D): 19.9, 25.2, 26.6, 30.4, 34.2, 36.4, 42.0, 51.7,
66.3, 128.4, 128.5, 128.8, 136.3, 173.2, 174.4; HRMS (EI-TOF, m/z): found
[M+Na] 315.1569, calc. for C17H24O4Na, 315.1572.

1-Benzyl 8-methyl 3-phenyloctanedioate (12b). To a solution of Cu(I)I (827
mg, 4.34 mmol) in THF (14.5 mL) was added phenyl lithium 2.0M (4.34 mL, 8.69
mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The reaction
mixture was cooled to -78 ºC. To the solution was added trimethylsilyl chloride
(TMSCl, 1.67 mL, 13.03 mmol) dropwise and then 1-benzyl 8-methyl oct-2enedioate 11 (400 mg, 1.45 mmol) stepwise at -78 ºC. The mixture was stirred
for 3 h at -78 ºC and then quenched by addition of an aqueous solution of
saturated NH4Cl: saturated NH4OH (1:1) until the color of the mixture turned to
blue ((NH3)4CuCl2(aq)). The mixture was washed with the aqueous solution of
saturated NH4Cl: NH4OH (1:1) (14.5 mL). The organic layer was collected and
the aqueous layer was extracted with diethyl ether (equal volume to the aqueous
layer). The combined organic layers were dried over anhydrous Na2SO4, filtered,
and concentrated. The residue was purified by column chromatography (diethyl
ether: petroleum ether 1:6) on silica gel to give 12b + 11 (3:1).
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1-Benzyl 8-methyl 3-(tert-butyl)octanedioate (12c). The synthesis was similar
that of 12b except the following reagents were used: Cu(I)I (827 mg, 4.34 mmol)
in THF (10.9 mL), tert-butyllithium 1.6M (5.43 mL, 8.69 mmol), TMSCl (1.67 mL,
13.03 mmol), and 1-benzyl 8-methyl oct-2-enedioate 11 (300 mg, 1.09 mmol).
The product was purified by column chromatography (diethyl ether: petroleum
ether 1:6) on silica gel to give 12c (313 mg, 89%).

1

H-NMR (δ, ppm,

CHLOROFORM-D): 0.84 (s, 9H), 1.05 (m, 1H), 1.17-1.35 (m, 2H), 1.47-1.62 (m,
3H), 1.68 (m, 1H), 2.10 (q, 1H), 2.23 (t, 2H), 2.41 (q, 1H), 3.64 (s, 3H), 5.09 (s,
2H), 7.34 (m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 25.5, 27.6, 28.5, 31.0,
33.8, 34.2, 36.3, 45.2, 51.6, 66.4, 128.4, 128.6, 128.7, 136.3, 174.3, 174.5; IR:
2952, 2869, 1737, 1457, 1367, 1151, 914, 737 cm-1. MS (ESI, m/z): found [M+
+Li] 341.28, calc. for C20H30O4Li, 341.23.

1-Benzyl 8-methyl 3-(2-ethylhexyl)octanedioate (12d). The synthesis was
similar to that of 12b except the following reagents were used: Cu(I)Br∙SMe2
(1.89 g, 9.19 mmol) in THF (15.3 mL), 2-ethylhexyllithium (10.09 mL, 18.38
mmol), TMSCl (3.52 mL, 27.57 mmol), and 1-benzyl 8-methyl oct-2-enedioate 11
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(400 mg, 1.53 mmol). The product was purified by column chromatography
(diethyl ether: petroleum ether 1:8) on silica gel to give 12d (485 mg, 81%). 1HNMR (δ, ppm, CHLOROFORM-D): 0.79 (m, 3H), 0.88 (t, 3H), 1.23-1.31 (m,
15H), 1.58 (m, 2H), 1.91 (m, 1H), 2.25-2.30 (m, 4H), 3.66 (s, 3H), 5.11 (s, 2H),
7.35 (m, 5H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 10.7, 14.40, 23.4, 25.4,

26.1, 28.9, 32.8, 33.1, 34.2, 36.1, 38.5, 44.4, 66.3, 128.4, 128.6, 128.8, 129.2,
130.4, 173.2, 173.5; IR: 2956, 2858, 1739, 1457, 1167, 912, 741 cm-1. MS (ESI,
m/z): found [M++K] 429.29, [M++Li] 397.36, [M++Na] 413.31, calc. for C24H38O4K,
429.65, C24H38O4Li, 397.50, C24H38O4Na, 413.55.

1-Benzyl 8-methyl 3-isopropyloctanedioate (12e). The synthesis was similar
that of 12b except the following reagents were used: Cu(I)I (875 mg, 4.59 mmol)
in THF (7.7 mL), isopropyl magnesium bromide 1.94M (2.37 mL, 4.59 mmol),
TMSCl (1.76 mL, 13.78 mmol) and 1-benzyl 8-methyl oct-2-enedioate 11 (200
mg, 0.77 mmol). The residue was purified by column chromatography (diethyl
ether: petroleum ether 1:6) on silica gel to give 12e (109 mg, 45%). 1H-NMR (δ,
ppm, CHLOROFORM-D): 0.80 (d, 3H), 0.84 (d, 3H), 1.16-1.33 (m, 4H), 1.59 (m,
2H), 1.70 (m, 1H), 1.78 (m, 1H), 2.18 (m, 1H), 2.27 (m, 3H), 3.65 (s, 3H), 5.10 (s,
2H), 7.35 (m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 18.4, 19.4, 25.1, 26.8,
29.7, 30.7, 34.0, 36.0, 40.7, 51.5, 66.1, 128.2, 128.3, 128.5, 136.1, 173.9, 174.2;
IR: 3033, 2954, 2873, 1737, 1458, 1332, 1261, 1008, 905, 750 cm-1; HRMS (EITOF, m/z): found [M+Na] 343.1883, calc. for C19H28O4Na, 343.1885.
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Methyl 6-methyl-8-oxo-8-(phenylamino)octanoate (13a). To a solution of
crude 1-benzyl 8-methyl 3-methyloctanedioate 12a (513 mg, 1.86 mmol) in ethyl
acetate (19 mL) was added 20% Pd(OH)2/C (261 mg, 0.372 mmol) and the
reaction mixture was purged with H2 gas for 30 s. The reaction solution was
stirred under H2 gas for 3 h and then filtered through a plug of Celite with ethyl
acetate (57 mL). The filtrate was concentrated to give 8-methoxy-3-methyl-8oxooctanoic acid as clear oil.

The crude residue, 8-methoxy-3-methyl-8-

oxooctanoic acid, was transferred to a flask and dissolved in 19 mL of
acetonitrile. TBTU (895 mg, 2.79 mmol), diisopropylethylamine (647 mL, 3.72
mmol), and aniline (254 mL, 2.79 mmol) was added to the flask. The reaction
mixture was stirred for 3 h. The mixture was then quenched with 19 mL of
saturated NaHCO3 solution, transferred to a separatory funnel and extracted with
ethyl acetate (equal volume to aqueous layer) at least 3 times. The combined
organic layers were dried over magnesium sulfate, filtered, and evaporated to oil.
Flash silica gel chromatography (1:6 diethyl ether: petroleum ether → 1:1 diethyl
ether: petroleum ether) afforded 274 mg of the anilide 13a as a clear oil (53%
over 3 steps).

1

H-NMR (δ, ppm, CHLOROFORM-D): 0.91 (d, 3H), 1.13-1.34

(m, 4H), 1.56 (m, 2H), 2.09 (m, 2H), 2.27 (m, 3H), 3.61 (s, 3H), 7.02 (t, 1H), 7.24
(t, 2H), 7.52 (d, 2H), 8.27 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 19.9,
25.1, 26.6, 30.9, 34.2, 36.5, 45.6, 51.8, 120.0, 124.4, 129.2, 138.2, 171.1, 175.3;
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IR: 3306, 2952, 2868, 1739, 1601, 1544, 1151, 913, 757 cm-1; HRMS (EI-TOF,
m/z): found [M+H] 278.1764, calc. for C16H24NO3, 278.1756, found [M+Na]
300.1584, calc. for C16H24NO3Na, 300.1576.

Methyl

6-(tert-butyl)-8-oxo-8-(phenylamino)octanoate

(13c).

A

similar

procedure to that for 13a was used, except for the following reagents: 20%
Pd(OH)2/C

(210

mg,

0.299

mmol)

and

1-benzyl

8-methyl

3-(tert-

butyl)octanedioate 12c (414 mg, 0.748 mmol) in ethyl acetate (7.5 mL), TBTU
(360 mg, 1.121 mmol) in acetonitrile (7.5 mL), diisopropyethylamine (521 mL,
2.99 mmol), aniline (102 mL, 0.748 mmol) and stirring for 4 h. The mixture was
then quenched with 7.5 mL of saturated NaHCO3 solution, transferred to a
separatory funnel and extracted with ethyl acetate (equal volume to aqueous
layer) at least 3 times. The organic layer was dried over magnesium sulfate,
filtered, and evaporated to oil. In this case, flash silica gel chromatography (1:6
diethyl ether: petroleum ether → 1:1 diethyl ether: petroleum ether) afforded 185
mg of the anilide 13c as a clear oil (58% over 2 steps). 1H-NMR (δ, ppm,
CHLOROFORM-D): 0.91 (s, 9H), 1.13 (m, 1H), 1.33 (m, 1H), 1.42 (m, 1H), 1.55
(m, 3H), 1.82 (m, 1H), 2.09 (q, 1H), 2.28 (t, 2H), 2.49 (q, 1H), 3.62 (s, 3H), 7.09
(t, 1H), 7.21 (bs, 1H), 7.31 (t, 2H), 7.50 (d, 2H);
CHLOROFORM-D):

13

C-NMR (δ, ppm,

25.5, 27.8, 28.4, 31.2, 34.0, 34.1, 45.1, 56.1, 62.8, 119.2,

124.3, 129.2, 134.7, 168.5, 171.3; IR: 3055, 2952, 2865, 1732, 1600, 1265, 741,
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706 cm-1; HRMS (EI-TOF, m/z): found [M+H] 320.2229, calc. for C19H29NO3,
320.2226, found [M+Na] 342.2048, calc. for C19H29NO3Na, 342.2045.

Methyl 8-ethyl-6-(2-oxo-2-(phenylamino)ethyl)dodecanoate (13d). A similar
procedure to that for 13a was used, except for the following reagents: 20%
Pd(OH)2/C

(345

mg,

0.492

mmol)

and

1-benzyl

8-methyl

3-(2-

ethylhexyl)octanedioate 12d (463 mg, 1.229 mmol) in ethyl acetate (12.3 mL),
TBTU (592 mg, 1.844 mmol) in acetonitrile (12.3 mL), diisopropyethylamine (856
mL, 4.916 mmol), aniline (168 mL, 1.844 mmol) and stirring for 3 h. In this case,
the mixture was quenched with 12.3 mL of saturated NaHCO3 solution,
transferred to a separatory funnel and extracted with CH2Cl2 (equal volume to
aqueous layer) at least 3 times. The organic layer was dried over magnesium
sulfate, filtered, and evaporated to oil. The product was purified by column
chromatography (diethyl ether: petroleum ether 1:8) on silica gel to give 13d (349
mg, 76%).

1

H-NMR (δ, ppm, CHLOROFORM-D): 0.81-0.87 (m, 6H),1.10-1.34

(m, 15H), 1.60 (m, 2H), 2.03 (m, 1H), 2.22-2.32 (m, 4H), 3.65 (s, 3H), 7.08 (t,
1H), 7.32 (t, 2H), 7.51 (d, 2H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 10.7,

14.4, 23.4, 25.3, 25.8, 26.0, 28.9, 33.1, 33.2, 33.6, 33.8, 36.2, 38.5, 43.2, 51.7,
120.0, 124.3, 129.2, 138.3, 171.4, 174.6; IR: 3322, 3066, 2956, 1740, 1661,
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1171, 912, 746, 694 cm-1; MS (ESI, m/z): found [M++Li] 382.41, [M++Na] 398.35,
[M++K]

414.31,

calc.

for

C23H37NO3Li,

382.49,

C23H37NO3Na,

398.53,

C23H37NO3K, 414.64.

Methyl

6-isopropyl-8-oxo-8-(phenylamino)octanoate

(13e).

A

similar

procedure to that for 13a was used, except for the following reagents: 20%
Pd(OH)2/C (88 mg, 0.125 mmol) and 1-benzyl 8-methyl 3-isopropyloctanedioate
12e (0.312 mmol) in ethyl acetate (3 mL), TBTU (150 mg, 0.468 mmol) in
acetonitrile (3 mL), diisopropyethylamine (218 mL, 1.248 mmol), aniline (43 mL,
0.468 mmol) and stirring for 3 h. In this case, the product was purified by column
chromatography (1:6 diethyl ether: petroleum ether → 1:1 diethyl ether:
petroleum ether) on silica gel to give 13e (71 mg, 75%). 1H-NMR (δ, ppm,
CHLOROFORM-D): 0.84 (d, 3H), 0.89 (d, 3H), 1.25-1.38 (m, 4H), 1.61 (m, 2H),
1.81 (m, 1H), 1.90 (m, 1H), 2.15 (q, 1H),

2.30 (t, 2H), 2.34 (q, 1H), 3.64 (s, 3H),

7.09 (t, 1H), 7.31 (t, 2H), 7.41 (bs, 1H), 7.51 (d, 2H);
CHLOROFORM-D):

13

C-NMR (δ, ppm,

18.9, 19.5, 25.3, 26.9, 29.7, 30.6, 34.1, 39.6, 41.1, 51.8,

120.0, 124.4, 129.2, 138.3, 171.8, 174.6; IR: 3297, 3140, 2954, 2870, 1739,
1601, 1368, 906, 757, 693 cm-1; HRMS (EI-TOF, m/z): found [M+H] 306.2071,
calc. for C18H28NO3, 306.2069, found [M+Na] 328.1884, calc. for C18H28NO3Na,
328.1889.
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N8-Hydroxyl-3-methyl-N1-phenyloctanediamide

(14a).

To

a

solution

of

NH2OH∙HCl (677 mg, 9.735 mmol) in methanol (10 mL) was added KOH (1.092
g, 19.469 mmol) at 0 ˚C in an acid-washed 25mL round-bottom flask.

After

stirring for 20 min, methyl 6-methyl-8-oxo-8-(phenylamino)octanoate 13a (270
mg, 0.974 mmol) was added and the mixture was stirred for 8 h at 0°C. The
reaction mixture was adjusting to pH 6 by adding concentrated aqueous
hydrochloric acid. The mixture was diluted with 30 mL of ethyl acetate, and
washed with 30 mL of distilled water. The organic layer was dried over
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by
column chromatography (9% methanol/CH2Cl2) on acid-washed silica gel to give
14a (159 mg, 58%) as a clear oil.

1

H-NMR (δ, ppm, METHANOL-D4): 0.98 (d,

3H), 1.24-1.44 (m, 4H), 1.61 (m, 2H), 2.02 (m, 1H), 2.09 (t, 2H), 2.16 (q, 1H),
2.34 (q, 1H), 7.07 (t, 1H), 7.29 (t, 2H), 7.52 (d, 2H);

13

C-NMR (δ, ppm,

METHANOL-D4): 18.7, 25.7, 26.3, 30.8, 32.5, 36.3, 44.4, 120.2, 124.0, 128.6,
138.6, 171.8, 172.9; IR: 3270, 2928, 2868, 1643, 1600, 1500, 1418, 1116, 977,
759, 693 cm-1; HRMS (EI-TOF, m/z): found [M+H] 279.1710, calc. for
C15H23N2O3, 279.1709, found [M+Na] 301.1531, calc. for C15H23N2O3Na,
301.1528.
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N8-Hydroxyl-N8, 3-diphenyloctanediamide (14b). The synthesis of methyl 6phenyl-8-oxo-8-(phenylamino)octanoate 13b was similar to that of 14a except the
following reagents were used: 20% Pd(OH)2/C (153 mg, 0.218 mmol) and 1benzyl 8-methyl 3-phenyloctanedioate 12b (0.546 mmol) in ethyl acetate (5.5
mL), TBTU (263 mg, 0.818 mmol) in acetonitrile (5.5 mL), diisopropyethylamine
(190 mL, 1.09 mmol), aniline (75 mL, 0.818 mmol) and stirring for 4 h. In this
case, the reaction mixture was quenched with 5.5 mL of saturated NaHCO3
solution, transferred to a separatory funnel and extracted with CH 2Cl2 (equal
volume to aqueous layer) at least 3 times. The organic layer was dried over
magnesium

sulfate,

filtered,

and

evaporated

to

oil.

Flash

silica

gel

chromatography (diethyl ether: petroleum ether 1:1) afforded the mixture of
phenyl substituted anilide 13b and α, β unsaturated anilide 13b´ as a clear oil.
To a solution of NH2OH∙HCl (696 mg, 10.721 mmol) in methanol (10.7 mL)
was added KOH (1.203 g, 21.442 mmol) at 0 ˚C in an acid-washed 25mL roundbottom flask.

After stirring for 20 min, the mixture of methyl 6-phenyl-8-oxo-8-

(phenylamino)octanoate 13b and α, β unsaturated anilide 13b´ (1.072 mmol)
was added and the reaction mixture was stirred for 8 h at 0°C. The rest of the
reaction procedure was similar to that for 14a. The residue was purified by
column chromatography (4% methanol/CH2Cl2) on acid-washed silica gel to give
14b (221 mg, 60% over 4 steps).

1

H NMR (δ, ppm, DIMETHYLSULFOXIDE-
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D6): 0.85-1.25 (m, 3H), 1.42 (m, 2H), 1.58 (m, 2H), 1.83 (t, bs, 2H), 2.57 (m, 2H),
3.07 (m, 1H), 6.97 (t, 1H), 7.14-7.27 (m, 7H), 7.47 (d, 2H), 8.61 (s, 1H), 9.80 (s,
1H), 10.25 (s, 1H); 13C-NMR (δ, ppm, METHANOL-D4): 25.5, 26.9, 32.5, 35.5,
42.8, 44.5, 120.4, 124.1, 126.4, 127.5, 128.4, 128.5, 138.4, 144.1, 171.7, 171.9;
IR: 3235, 3027, 2928, 2859, 1874, 1641, 1599, 1544, 1498, 1467, 1116, 977,
757,699 cm-1; HRMS (EI-TOF, m/z): found [M+H] 341.1877, calc. for C20H25N2O3,
341.1865, found [M+Na] 363.1697, calc. for C20H25N2O3Na, 363.1685.

3-(tert-Butyl)-N8-hydroxyl-N1-phenyloctanediamide (14c). A similar procedure
to that for 14a was used, except for the following reagents: NH2OH∙HCl (348 mg,
5.008 mmol) in methanol (7.4 mL), KOH (562 mg, 10.018 mmol), methyl 6-(tertbutyl)-8-oxo-8-(phenylamino)octanoate 13c (160 mg, 0.501 mmol) and stirring for
4 h. In this case, the product was purified by column chromatography (4 %
methanol/CH2Cl2) on acid-washed silica gel to give 14c (158 mg, 99%).

1

H-

NMR (δ, ppm, METHANOL-D4): 0.92 (s, 9H), 1.15 (m, 1H), 1.28 (m, 1H), 1.40
(m, 1H), 1.58 (m, 3H), 1.77 (m, 1H), 2.04 (t, 2H), 2.16 (q, 1H), 2.53 (q, 1H), 7.07
(t, 1H), 7.29 (t, 2H), 7.50 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4): 26.1, 26.7,
28.6, 30.8, 32.6, 33.3, 38.5, 45.0, 120.2, 123.9, 128.6, 138.8, 171.8, 173.9; IR:
3350, 2956, 2870, 1938, 1648, 1547, 1500, 1119, 976, 757, 693 cm-1; HRMS (EITOF, m/z): found [M+H] 321.2180, calc. for C18H29N2O3, 321.2178, found [M+Na]
343.1998, calc. for C18H29N2O3Na, 343.1988.
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3-(2-Ethylhexyl)-N8-hydroxyl-N1-phenyloctanediamide

(14d).

A

similar

procedure to that for 14a was used, except for the following reagents:
NH2OH∙HCl (629 mg, 9.054 mmol) in methanol (9 mL), KOH (1.016 g, 18.108
mmol), methyl 8-ethyl-6-(2-oxo-2-(phenylamino)ethyl)dodecanoate 13d (340 mg,
0.905 mmol), and stirring for 6 h. In this case, the product was purified by column
chromatography (4 % methanol/CH2Cl2) on acid-washed silica gel to give 14d
(199 mg, 58%).

1

H-NMR (δ, ppm, METHANOL-D4): 0.85 (m, 6H), 1.19-1.37 (m,

16H),1.61 (m, 2H), 2.02 (bs, 1H), 2.09 (t, 2H), 2.24 (m, 2H), 7.07 (t, 1H), 7.29 (t,
2H), 7.53 (d, 2H);

13

C-NMR (δ, ppm, METHANOL-D4):

9.7, 9.9, 13.4, 23.0,

26.0, 28.5, 28.8, 32.6, 32.8, 33.0, 34.0, 36.1, 38.4, 42.3, 120.1, 124.0, 128.6,
138.7, 171.8, 173.1; IR: 3391, 3256, 3065, 2956, 1643, 1600, 1539, 1500, 1308,
903, 756, 692 cm-1; HRMS (EI-TOF, m/z): found [M+H] 377.2798, calc. for
C22H37N2O3, 377.2804.

3.5

HDAC assay procedure
HDAC activity was measured using the Fluor de Lys® activity assay

(Enzo) using the manufacturer’s protocol. To measure global HDAC inhibition,
HeLa lysates (approximately 4µg of total protein) were incubated with small
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molecule inhibitor or without small molecule inhibitor (2% DMSO) in HDAC assay
buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) in a final
volume of 25 µL for 20 min at 23 ˚C with 600 rmp shaking.

Concentrations of

small molecule between 1 nM and 1 mM were used to determine IC 50 values
(Appendix C. Table C.1-C.6).

Because the small molecules were stored in

DMSO, dilution with HDAC buffer ensured that a maximum of 2% DMSO was
present in the final reaction mixture.

After the initial incubation, Fluor de Lys®

substrate in HDAC assay buffer (100 µM final concentration) was added to make
a total reaction volume of 50µL. The reaction mixture was incubated at 30˚C for
30 min with 600 rmp shaking. To quench the reaction and allow color
development, Fluor de Lys® developer (2.5 µL of 20X diluted up to 50 µL in
HDAC assay buffer ) was added to give a final 100 µL volume and incubated with
shaking for 5 min at room temperature. The fluorescence intensity was
determined using a Geniosplus Fluorimeter (Tecan) with excitation at 360 nm
and emission at 465 nm.
To perform the isoform selectivity studies, the procedure was similar
except that the HeLa cell lysates were replaced with 0.2 µg HDAC1 (specific
activity = 42.5 pmol/min/µg), 0.05 µg HDAC3 (specific activity = 249 pmol/min/µg)
or 0.25 µg HDAC6 (specific activity = 257 pmol/min/µg), purchased from Enzo
Life Sciences.

In addition, the Fluor de Lys® substrate was used at a final

concentration of 50 µM for HDAC1 and HDAC6 or 25µM for HDAC3.
For each trial, a no enzyme control sample was used to assess the
background. The background-corrected fluorescence units of small molecule-
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treated samples were then compared to that of untreated samples (set to 100%)
to give a percentage deacetylase activity. IC50 values were obtained by plotting
the percentage deacetylase activity versus the small molecule concentration and
fitting the data to a sigmoidal dose-response curve (y=100/(1+(x/m3)m4) using
KaleidaGraph software where m1 is the IC50 value in Molar units.

All

experiments were performed in triplicate with the mean and standard error
reported in the tables and figures.
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CHAPTER 4 – SYNTHESIS OF SAHA ANALOGUES MODIFIED AT THE C7
POSITION

4.1

Rationale for design of the SAHA analogues modified at the C7
position
SAHA analogues with substituents on C2 and C3 position displayed

decreasing inhibitory activity while C6-SAHA analogues displayed similar
potency to the parent compound, SAHA. These results indicate that only limited
steric environment exists near hydroxamic acid. For example, the C6-SAHA
analogue with the phenyl substituent displayed only 4-fold decreased inhibition
while the C3-SAHA analogue with the phenyl substituent displayed more 800-fold
decreased inhibitory activity compared to SAHA. Based on an analysis of the
HDAC crystal structure (Figure 1.4)54, more space near the capping group area is
available to accommodate bulky groups compared to the area near the
hydroxamic acid. Moreover, large capping groups have been synthesized and
displayed nM range inhibition.21b, 38 Several class-selective HDAC inhibitors have
been synthesized that contain large groups in capping group region.20 Therefore,
design, synthesis, and evaluation of a C7-SAHA library (Figure 4.1) are
necessary to elucidate the structural requirement of HDAC inhibitors, since C7SAHA analogues are located closest to the solvent-exposed region through the
linker area.
C7-SAHA

analogues

with

hydrophobic substituents were generated.
Figure 4.1. Structure of SAHA analogues
containing substituents on the C7 position

Synthesizing C7-SAHA analogues with
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only hydrophobic substituents might be sub-optimal since the C7 position is
between the hydrophobic tunnel and the solvent exposed area. Therefore, we
synthesized the methyl pyridyl variant to study the influence of polar groups. In
addition, since medicinal and natural compounds containing nitrogen were
involved in diverse therapeutic areas (Chapter 1), we chose the pyridyl
derivative.41-42, 55 Since hydrophobic substituents attached at the C6 position, a
position that is close to the solvent-exposed location, displayed more potent
inhibition compared to the C2 and C3-SAHA libraries, C7-SAHA analogues might
also display potent inhibition compared to the C2, C3, and C6-SAHA analogues.
Therefore, large aromatic groups should be incorporated on the C7 position. We
designed a variety of substituents from the small methyl substituent to the large
4-methylnaphthyl,

methylbiphenyl,

methylanthracene,

and

methyltetrahydroanthracene substituents to address what effect large groups
impart on potency. Due to the structural similarity to the previously reported C2SAHA analogues, a straightforward synthetic approach was envisioned.

4.2

Initial synthesis of C7-SAHA analogues
Initially, C7-SAHA analogues with methyl 22a, benzyl 22b, and 4-

methylnaphthyl 22c substituents were synthesized by Dr. A. Bieliauskas. The
early synthetic route for C7-SAHA analogues is outlined in Scheme 4.1.
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Scheme 4.1. Initial synthesis of C7-SAHA analogues 22a-22c

Benzyl ester 16 was obtained by coupling conditions with benzyl alcohol
and 6-bromohexanoic acid 15. t-Butyl malonate derivatives 17 after nucleophilic
substitution reaction provided the scaffold to create alkylated malonate
derivatives 18a-c. In acidic conditions, the t-butyl groups in 18a-c were
deprotected and decarboxylation was accomplished under reflux to give
monocarboxylic acid 19a-c, which was coupled with aniline. The benzyl group in
20a-c was removed by Pd/C, and was coupled with O-benzyl-protected
hydroxamine. O-benzyl-protected hydroxamic acid 21a-c was deprotected by
hydrogenolysis to give the C7- SAHA methyl, benzyl, and methylnaphthyl 22a-c.
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HDAC inhibitory activities of the C7-methyl, benzyl, and 4-methylnaphthyl
SAHA analogues 22a-c were measured using the Fluor de Lys™ in vitro
fluorescence activity assay kit (Biomol) by Dr. S. V. W. Weerasinghe (Table 4.1).

Table 4.1. HDAC inhibition by SAHA, C7-methyl, benzyl, and 4-naphthyl variants
using HeLa cell lysates
Compounds
R
IC50, nMª
86  4

SAHA
22a

Methyl

105  6

22b

Benzyl

109  5

22c

1-Naphthylmethyl

16  1

ªValues are the mean of at least three experiments with standard error given.

The C7-methyl and benzyl analogues 22a-b were equipotent in 100 nM
range similar to SAHA (86 nM). The inhibition results are consistent with the
hypothesis that greater steric tolerance exists in HDAC active site at the entrance
area of capping group than the metal binding moiety region. Moreover, the
largest compound, C7-SAHA naphthylmethyl analogue 22c among three
analogues, displayed greater than 5-fold increasing inhibitory activity compared
to SAHA. The addition of certain groups at the C7 position showed favourable
interaction between the entrance area of HDAC active site and large bulky
groups at the C7 position.
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4.3

Synthesis of the C7-SAHA analogues with pyridyl and bulky

substituents
To thoroughly explore the impact of the large bulky groups at the C7
position, additional large groups should be investigated. For example, the 4methylbiphenyl and 9-methylanthracene variants 22e-f should be synthesized to
verify how large groups at the C7 position could interact with the HDAC active
site. In addition, the inclusion of polar groups should be included to validate
interaction between HDAC active site and hydrophilic substituents at the C7
position, the end edge of the hydrophobic channel. However, the synthesis of
C7-SAHA analogues containing bulkier and larger substituents than the methyl,
benzyl, and 4-methylnaphthyl variants 22a-c faced issue in the nucleophilic
substitution

reaction

(17->18)

(Scheme

4.1).

Therefore,

the

synthesis

methodology was redesigned (Scheme 4.2). First of all, we used commercially
available methyl 6-bromohexanoate 23 as the starting material instead of using
coupling reaction to obtain benzylester 16 (two-step) (Scheme 4.1). Second, the
nucleophilic substitution reaction was accomplished with dibenzylmalonate,
which has a planar structure compared to the bulky t-butylmalonate (Scheme
4.1) to give the dibenzylmalonate derivatives 24 (Scheme 4.2). Finally, direct
conversion to hydroxamic acid 22 was accomplished in one step without
saponification, coupling O-benzyl hydroxylamine, and benzyl deprotection.47 The
4-(1,1'-Biphenyl)methyl variant 22e was synthesized by Geetha Padige, the 9anthracenylmethyl

22f

and

9-(1,2,3,4-tetrahydroanthracenyl)methyl

22g
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derivatives

were synthesized by Satish Garre, and the 4-pyridylmethyl variant

22d was synthesized under my responsibility.
The alternative synthetic route of the C7-SAHA library had been designed
by the main concern for bulky subsitutuent attachment when the nucleophilic
substitution (24->25) reaction was performed with large groups. Additionally,
several steps were improved in Scheme 4.2.

Scheme 4.2. Redesigned synthesis of C7-SAHA library for bulky groups

After

successful

nucleophilic

substitution

reaction

with

the

dibenzylmalonate derivatives 24 and remaining substituents (pyridylmethyl,
biphenylmethyl, and anthracenylmethyl groups), alkylated malonate derivatives
25d-f were deprotected by Pd/C under hydrogen gas. Interestingly, the pyridyl
and anthracenylmethyl groups were reduced when the dibenzyl groups of
compounds 25d-f were deprotected. Zacharie and co-workers have proven the
reduction from pyridine derivatives to piperidine derivatives in the mild
condition.56 After deprotection by Pd/C, decarboxylation under the reflux
condition, and coupling with aniline (three-step), there were additional anilide
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products, the anthracenylmethyl anilide derivative 26f and the tetrahydroanthracenylmethyl anilide derivative 26g. In contrast, pyridyl and piperidylmethyl
anilide derivatives 26d, 26d´ were unable to be isolated. The anthracenylmethyl
and tetrahydroanthracenylmethyl anilide derivatives 26f, 26g were directly
convert to hydroxamic acid 22f, 22g.
4.4

Optimized synthesis for the C7-pyridyl analogue
To synthesize the C7-pyridyl hydroxamic acid 22d, the synthetic method

was redesigned since the pyridyl and piperidylmethyl anilide derivatives were not
isolated (Scheme 4.3). The initial synthesis performed by Dr. Bieliauskas was
modified since the pyridylmethyl group is smaller than naphthylmethyl group.
However, several reaction conditions were improved.
First of all, benzyl ester 16 was obtained under Fisher condition (95%
yield) with benzyl alcohol and 6-bromohexanoic acid 15 instead of the coupling
reaction (80% yield). The nucleophilic substitution reaction with t-butyl malonate
generated derivative 17, which was alkylated with bromomethyl pyridine to
produce alkylated malonate derivatives 18d. Compared to Dr. Bieliaskas’
synthesis, the alkylation was performed under the kinetic condition in DMF at 0
ºC (16 in 99%

yield and 18d in 55% yield) for shorter time (2-3h). Under acidic

condition, the t-butyl groups on compound 18d were deprotected and
decarboxylation was observed under reflux to give the monocarboxylated
derivative. Without purification, the coupling reaction was performed to give
anilide 20d (yield 99% over three steps). To obtain the final C7-SAHA
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pyridylmethyl hydroxamic acid 22d, direct conversion was achieved in one step
(43%).

Scheme 4.3. Redesigned and optimized synthesis for C7-SAHA
pyridylmethyl analogue 22d

4.5

Biological analysis
HDAC inhibitory activities of the remaining C7-SAHA analogues were

measured using the Fluor de Lys® in vitro fluorescence activity assay kit using
Hela cell lysates (Table 4.2). HDAC inhibition of biphenylmethyl variant 22e was
tested by Geetha Padige.
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Table 4.2. HDAC inhibition by C7-SAHA analogues and SAHA using HeLa cell
lysates
Compounds
R
IC50, nMª
86  4

SAHA
22d

4-Pyridylmethyl

450  35

22e

4-(1,1'-Biphenyl)methyl

4  0.3

22f

9-Anthracenylmethyl

20  1

22g

9-(1,2,3,4-Tetrahydroanthracenyl)methyl

102  30

ªValues are means of more than three experiments with standard error given.

One of the large compounds, C7-SAHA 4-(1,1´-biphenyl)methyl analogue
22e displayed greater than 22-fold increase in inhibitory activity compared to
SAHA (86 nM) or the smallest compound C7-SAHA methyl analogue 22a (105
nM). Variants 22b, 22e with the large groups, such as naphthylmethyl and
biphenylmethyl, were more potent than the smallest variant 22a with methyl
group for C7-SAHA inhibitory activities (Table 4.2). However, the bulky
tetrahydroanthracenylmethyl subtituents displayed potency similar to SAHA. The
data suggest that C7-SAHA analogues with planar aromatic groups interacted
favourably in the binding area of HDAC active site. Moreover, the addition of
certain groups at the C7 position likely promotes interaction between the
entrance area of HDAC active site and the inhibitor.
Even though we found that greater steric tolerance exists in the HDAC
active site in the entrance area of the capping group than the metal binding
moiety region, the pyridylmethyl analogue displayed the weakest inhibitory
activity (IC50 450 nM). The polarity of the nitrogen atom might interact
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unfavorably the binding area of the HDAC active site. As a result, the potency
was influenced not only by the size of subsitutuents, but also the polarity, as
shown by the fact that the pyridylmethyl group of equal size to the benzyl group
(IC50 109 nM).
To more thoroughly verify the structural requirements of SAHA analogues,
the isoform selectivity of the C7-SAHA analogues was tested by using HDAC1
and HDAC3 representing class I and HDAC6 representing class II (Figure 4.2).
To assess the isoform selectivity of the C7-SAHA analogues, all compounds
were initially tested at a single concentration near to their IC50 values using the
Fluor de Lys® kit (Enzo).
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Figure 4.2. Screen of C7-SAHA analogues against HDAC1, HDAC3, and HDAC6 with
100 nM methyl, benzyl, tetrahydroanthracenylmethyl, and biphenylmethyl (22a, 22b, 22g, and
22e) variants, 500 nM pyridylmethyl and anthracenylmethyl variants (22d and 22f), and 10 nM
naphthylmethyl variant (22c).

The methyl 22a, and benzyl 22b variants showed similar inhibition for
HDAC1, HDAC3, and HDAC6 at 100 nM, despite slight selectivity for HDAC6
over HDAC1 and HDAC3. The biphenyl variant 22e, which displayed the most
potent inhibition from using Hela cell lysates, showed a slightly preference for
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HDAC6 over HDAC1 and HDAC3 as well. In this case, however, two flexible
perpendicular aromatic groups might enhance interaction with all of HDAC
protein active sites to increase potency, not selectively. In addition, the
biphenylmethyl variant 22e did not show inhibition at 10 nM concentration near to
the Hela cell lysate IC50 value (4 nM) for HDAC1, HDAC3, and HDAC6. In
contrast, the naphthylmethyl 22c and tetrahydroanthracenylmethyl 22g variants
showed greater potency for HDAC3 over HDAC1 and HDAC6 at 10 nM and 100
nM. Interestingly, both compounds contain two planar aromatic groups.
Moreover, the pyridylmethyl 22d and anthracenylmethyl 22f variants showed
unique dual-selective inhibition at 500 nM for HDAC1 and HDAC6 over HDAC3.
Surprisingly, the C7-SAHA anthracenylmethyl compound 22f was unable to
inhibit when tested at 10 nM concentration near to the Hela cell lysate IC50 value
(20 nM). After several screening, we found that the anthracenylmethyl variant 22f
inhibited 50% at 500 nM against HDAC1 and HDAC6. The biphenylmethyl 22e
and anthracenylmethyl 22f variants might display more selective inhibition for
other HDAC proteins, such as HDAC2, HDAC4, HDAC5, HDAC7, HDAC8, and
HDAC10 due to the fact that showed inhibition at 25-time higher concentration
(100 nM and 500 nM) against HDAC1, HDAC3, and HDAC6 than their Hela cell
lysate IC50 values (4 nM and 20 nM).

87
With the potential of chemotherapeutic use of selective HDAC inhibitors,
several class-selective and isoform-selective HDAC inhibitors have been studied.
Most of selective HDAC inhibitors displayed preference for HDAC1 or HDAC8
against HDAC3.17b,

20, 38b, 57-58

For example, compounds 27a

Figure 4.3. HDAC inhibitors modified at the linker regions
with two parallel aligned aromatic groups

preference

for

HDAC8

(Figure

4.3).38b

and 27b,

which have two-

aromatic

group,

Nevertheless,

the

showed
C7-SAHA

naphthylmethyl analogue 22c and tetrahydroanthracenylmethyl analogue 22g
containing similar structures to the compounds 27a and 27b display unique
HDAC3 selectivity. Two parallel aligned aromatic group subsitutuents on the
linker region may influence selectivity due to the presence of favorable π-π
interactions with particular HDAC active site. Additionally, a dual-selective
HDAC1 and HDAC6 inhibitor (pyridyl 22d and anthracene 22f) might promote
design of drugs. Therefore, studying the C7-SAHA analogues, which displayed
HDAC3

selective

inhibition

(the

naphthylmethyl

22c

and

tetrahydro-

anthracenylmethyl 22g) and dual-HDAC1 and HDAC6 selective inhibition (the
pyridylmethyl 22d and anthracenylmethyl 22f variants), might be a great starting
point to develop a variety of dual or isoform-selective HDAC inhibitors.
To more thoroughly assess the selectivity observed in the initial screen,
we determined individual HDAC1, HDAC3, and HDAC6 IC50 values of the
anthracene variant 22f, and SAHA as a comparison. Pathological cardiac
remodeling studies have been reported using selective HDAC inhibitors (Section
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1.9). Specifically, development of dual-selective inhibitors has been an attractive
target in pharmacokinetic study due to the hypothesis by that cancer formation is
more complex than related to only single isoform HDAC protein. However, a lack
of information on dual-selective HDAC inhibitors is a current challenge. For
promising chemotherapeutic use, the anthracenylmethyl analogue 22f among
C7-SAHA analogues, which displayed dual-selective inhibition for HDAC1 and
HDAC6, was analyzed by using the Fluor de Lys® kit (Enzo). The C7anthracenylmethyl analogue 22f displayed 4-fold selectivity for HDAC1 over
HDAC3 and 3-fold class selectivity for HDAC6 over HDAC3 (Table 4.3). In
addition, it displayed selectivity within class I, with 4-fold preference for HDAC1
over HDAC3. As a control, SAHA displayed non-selective inhibitor activity
against the isoform, as expected (Table 4.3).30 The selectivity analysis shows
that substituents on the C7 position can influence selectivity. As a comparison,
the C6-SAHA t-butyl analogue (dual-HDAC1 and HDAC6 selective inhibitor, IC50
value of 1.9 µM) displayed 22-fold less potency compared to SAHA (86 nM) while
the C7-SAHA anthracene analogue 22f (20 nM) showed 4-fold better potency
compared to SAHA. Therefore, the data indicate that attaching the anthracene
substituent on the linker chain on the C7 position promotes selectivity with
potency.
Table 4.3. IC50 values of SAHA and the C7-SAHA anthracene 22f for HDAC1,
HDAC3, and HDAC6
Compound
IC50/nM
HDAC1

HDAC3

HDAC6

SAHA

96 ± 16

136 ± 11

74 ± 9

22f

300 ± 66

1200 ± 50

443 ± 73

89

SAHA analogues with substituents on the C7 position displayed selective
inhibition, including dual-class I, II selectivity (pyridyl 22d and anthracene 22f
variants)

and

isoform

selectivity

tetrahydroanthracne 22g variants)

for

HDAC3

(naphthyl

22c

and

and HDAC6 (biphenyl variant 22e). The

results reveal that small structural changes in the C7 position linker region of
SAHA will lead in designing drugs by improving selectivity and potency compared
to the broad-spectrum inhibitor SAHA. Furthermore, studying selective inhibitor
structures in detail will be able to be explored through our selective compound
analysis in a variety of scope.

4.6

Future direction
We have synthesized and analyzed SAHA analogues that placed a variety

of substituents in the carbon linker. The results from the C3, C6, and C7 library
suggest that SAHA analogues with substituents on the carbon linker are
promising to develop new anti-cancer drugs. To more systematically assess the
structural effect in HDAC active site, more analogues positioning subsituetns at
the C4, and C5
positions should
be
Figure 4.4. Structures of SAHA analogues containing substituents on the
C4 and C5

synthesized

(Figure 4.4). In

addition, analysis of isoform selectivity of the C3-SAHA analogues suggests that
substituents on the SAHA linker influence selectivity. We have shown that the
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steric environment of the C6 position displays less influences on potency
compared to SAHA analogues with substituents near the hydroxamic acid.
However, substituents at α-carbon on C6 position still decreased inhibitory
activity. Interestingly, despite the poor potency of the C6-SAHA t-butyl analogue,
it displayed selectivity. Likewise, the C3-SAHA ethyl analogue with an additional
methylene group at the α–carbon compared to the C3-SAHA methyl analogue
displayed selective inhibition (HDAC6 selectivity). The effect of the α-carbon on
C6 substituents could be thoroughly investigated with the synthesis of isopropyl
and adamantyl group analogues. Besides, the long chain of the 2-ethyl hexyl
SAHA analogues on the C6 position also affected isoform selectivity (HDAC3selectivity) with potency. Favourable interactions of the long aliphatic chain in
HDAC active site could be verified through synthesis of C6-SAHA octyl to
undecyl analogues. Furthermore, C7-SAHA analogues show potent inhibition
with large and polar group substituents. The influence of the enantiomers with
bulky or polar groups near the capping group would allow assessing the
structural requirements of the compounds in detail. Therefore, screening the
enantiomers of all SAHA analogues might show promising properties. Moreover,
testing the inhibitory activities against all HDAC proteins, from HDAC1 to
HDAC11, will provide the structures of selective inhibitors. Developing new costeffective, high through-put screening methods are needed to test selectivity
against all HDAC1-11. Therefore, the biological evaluation of the current
compound

enantiomers,

the

additional

synthesis

of

different

structural
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compounds, and the development of easy-access high through-put assay will
contribute to develop promising cancer drugs.
4.7

Experimental

4.7.1 General methods
Additional details were shown in Section 2.5.1 of Chapter 2.
4.7.2 Experimental Procedures and Compound Characterizations

1, 1-Dibenzyl 6-methyl hexane-1, 1, 6-tricarboxylate (24). To a solution of NaH
(144 mg, 6 mmol) in DMF (20 mL) was added dibenzylmalonate (1.14 mL, 6
mmol) dropwise at 0 ºC and the mixture was stirred for 15 min. To the solution
was added methyl 6-bromohexanoate 23 (0.57 g, 2 mmol) and the mixture was
stirred for 3 h. The mixture was filtered through celite with ethyl acetate and
concentrated. The residue was purified by column chromatography (diethyl
ether:petroleum ether 1:19) on silica gel to give 24 (682 mg, 81%).

1

H-NMR (δ,

ppm, CHLOROFORM-D): 1.31 (m, 4H), 1.58 (m, 2H), 1.94 (q, 2H), 2.26 (t, 2H),
3.43 (t, 1H), 3.65 (s, 3H), 5.14 (s, 4H), 7.31 (m, 10H);

13

C-NMR (δ, ppm,

CHLOROFORM-D): 24.8, 27.1, 28.8, 28.9, 34.1, 51.7, 52.1, 67.3, 128.4, 128.6,
128.8, 135.6, 169.4, 174.3; IR: 3033, 2949, 2862, 1734, 1498, 1456, 1333, 1214,
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1156, 907, 741, 698 cm-1; HRMS (EI-TOF, m/z): found [M+Na] 435.1767, calc.
for C24H28O6, 435.1784.

6, 6-Dibenzyl 1-methyl 7-(pyridine-4-yl)heptane-1, 6, 6-tricarboxylate (25). To
a solution of NaH (256 mg, 6.4 mmol) in DMF (53 mL) was added 1, 1-dibenzyl
6-methyl hexane-1, 1, 6-tricarboxylate 24 (2.20 g, 5.33 mmol) dropwise at 0 ºC
and the mixture was stirred for 15 min. Separately, 1.5 equivalents of 4-bromomethylpyridine hydrobromide salt (2.02 g, 8.00 mmol) was dissolved in distilled
water (8 mL) and added to a separatory funnel, followed by 0.7 equivalent of
Na2CO3 (396 mg, 3.74 mmol). After the separatory funnel was shaken until gas
evolution was not observed, the mixture was extracted with ethyl acetate (8 mL)
at least 4 times. The organic layers were dried over magnesium sulfate, filtered,
and concentrated by rotary evaporation. To the flask containing the activated
dibenzyl malonate derivatives solution 24 was added the solution of the
neutralized and concentrated 4-bromo-methylpyridine and the mixture was stirred
for 4h at 0 ºC. The reaction was quenched with distilled water (26.5 mL) and
extracted with ethyl acetate (equal volume to aqueous layer). The organic layer
was pooled and extracted with distilled water (equal volume to organic layer) at
least 4 times. The organic layer was dried over magnesium sulfate, filtered, and
concentrated to oil. The residue was purified by column chromatography (ethyl
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acetate:hexanes 1:3) on silica gel to give 25 (1.61 g, 60%).

1

H-NMR (δ, ppm,

CHLOROFORM-D): 1.21 (m, 4H), 1.50 (m, 2H), 1.75 (t, 2H), 2.20 (t, 2H), 3.19 (s,
2H), 3.64 (s, 3H), 5.08 (s, 4H), 6.82 (d, 1H), 6.91 (d, 1H), 7.24-7.31 (m, 7H), 8.35
(d, 1H), 8.36 (d, 1H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 24.1, 24.8, 29.3,

32.3, 34.0, 37.8, 51.7, 58.7, 67.5, 125.3, 128.765, 128.787, 128.816, 135.3,
145.3, 149.9, 170.6, 174.1; IR: 3032, 2951, 1731, 1601, 1455, 1218, 1170, 912,
733, 698 cm-1; HRMS (EI-TOF, m/z): found [M+H] 504.2387, calc. for C30H34NO6,
504.2386.

Benzyl 6-bromohexanoate (16). Benzyl alcohol (0.07 mL, 0.68 mmol) and
concentrated aqueous sulfuric acid (3 µL, 0.056 mmol) were stepwise added to a
solution of 6-bromohexanoic acid 15 (0.11 g, 0.56 mmol) in diethyl ether (5 mL)
at 0ºC. The mixture was stirred for 30min and warmed to room temperature. The
reaction mixture was quenched with distilled water (5 mL). The mixture was
extracted with diethyl ether (5 mL) at least 4 times. The organic layer was
evaporated. The concentrated organic layer was extracted with distilled water
(equal volume to the concentrated organic layer) at least 3 times. The organic
layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue
was purified by column chromatography (diethyl ether:petroleum ether 1:19) on
silica gel to give 16 (153 mg, 95%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.47
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(m, 2H), 1.68 (m, 2H), 1.86 (m, 2H), 2.38 (t, 2H), 3.38 (t, 2H), 5.12 (s, 2H), 7.36
(m, 5H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 24.3, 27.9, 32.6, 33.7, 34.3,

66.4, 128.5, 128.8, 136.3, 173.5; IR: 3033, 2939, 1733, 1455, 1254, 1165, 736,
697 cm-1; HRMS (EI-TOF, m/z): found [M+Na] 307.0314, calc. for C13H17O2NaBr,
307.0310.

6-Benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate (17). To a solution of
NaH (589 mg, 14.7 mmol) in DMF (49 mL) was added di-t-butylmalonate (3.30
mL, 14.7 mmol) dropwise at 0 ºC and the mixture was stirred for 15 min. To the
solution was added benzyl 6-bromohexanoate 16 (1.4 g, 4.91 mmol) at 0 ºC and
the mixture was stirred for 3 h at room temperature. The mixture was filtered
through celite with ethyl acetate and concentrated. The residue was purified by
column chromatography (diethyl ether:petroleum ether 1:19) on silica gel to give
17 (2.04 g, 99%).1H-NMR (δ, ppm, CHLOROFORM-D): 1.34 (m, 4H), 1.45 (s,
18H), 1.65 (m, 2H), 1.79 (q, 2H), 2.34 (t, 2H), 3.10 (t, 1H), 5.11 (s, 2H), 7.35 (m,
5H);

13

C-NMR (δ, ppm, CHLOROFORM-D): 24.9, 27.1, 28.2, 28.6, 29.0, 34.4,

54.1, 66.3, 81.5, 128.4, 128.8, 135.6, 169.1, 173.7; IR: 3033, 2979, 2935, 2861,
1729, 1498, 1369, 1256, 1169, 1139, 748 cm-1; found MS(ESI): m/z = 427.30
(M++Li), 443.30 (M++Na), 459.27 (M++K), calc. for C24H36LiO6, 427.48,
C24H36NaO6, 443.53, C24H36KO6, 459.64.
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1-Benzyl 6,6-di-tert-butyl 7-(pyridine-4-yl)heptane-1,6,6-tricaboxylate (18d).
To NaH (171 mg, 4.28 mmol) and

4-bromo-methylpyridine hydrobromide salt

(1.0 g, 4.28 mmol) was added DMF (16 mL) dropwise at 0 ºC and the mixture
was stirred for 20min. Separately, to NaH (171 mg, 4.28 mmol) in DMF (20 mL)
was added 6-benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate 17 (1.5 g, 3.57
mmol) dropwise at 0 ºC and the mixture was stirred for 20 min. To the solution of
the activated 6-benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate 17 was added
the solution of the neutralized 4-bromo-methylpyridine dropwise at 0 ºC and the
mixture was stirred for 3h at room temperature. The reaction mixture was filtered
through celite with ethyl acetate and concentrated. The residue was purified by
column chromatography (diethyl ether:petroleum ether 1:5) on silica gel to give
18d (513 mg, 55%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.29 (m, 4H), 1.43 (s,
18H), 1.65 (m, 4H), 2.34 (t, 2H), 3.12 (s, 2H), 5.10 (s, 2H), 7.07 (d, 2H), 7.34 (m,
5H), 8.47 (d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-D): 24.0, 24.9, 28.1, 29.5,
32.2, 34.4, 37.4, 59.1, 66.4, 82.0, 125.6, 128.4, 128.8, 136.2, 146.3, 149.7,
170.3, 173.6; IR: 3036, 2976, 2935, 2867, 1727, 1605, 1248, 1159, 846, 737,
696 cm-1; HRMS (EI-TOF, m/z): found [M+H] 512.3016, calc. for C30H42NO6,
512.3012.
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Benzyl 8-oxo-8-(phenylamino)-7-(pyridine-4-ylmethyl)octanoate (20d). To a
flask equipped with a reflux condenser and containing 1-benzyl 6,6-di-tert-butyl
7-(pyridine-4-yl)heptane-1,6,6-tricaboxylate 18d (510 mg, 997 mmol) was added
10 mL of 10% TFA in acetic acid. The reaction mixture was refluxed overnight
and evaporated to oil. The residue was dissolved in ethyl acetate (10 mL) and
transferred to a separatory funnel. The solution was extracted with saturated
NaHCO3(aq) (equal volume to organic layer) at least 4 times. The organic layer
was dried over magnesium sulfate, filtered, and evaporated. The crude residue
was dissolved in acetonitrile (10 mL). To the solution of crude carboxylic acid
derivative was added individually in order listed in a stepwise: TBTU (480 mg),
diisopropylethylamine (695 mL), and aniline (136 mL). The reaction mixture was
stirred overnight at room temperature. The reaction was quenched by addition of
an aqueous solution of saturated NaHCO3 (10 mL). The mixture was extracted
with CH2Cl2 (equal volume to aqueous layer) at least 4 times. The organic layer
was dried over magnesium sulfate, filtered, and concentrated to an oil. The
residue was purified by column chromatography (ether:petroleum ether 1:1) on
silica gel to give 20d (572 mg, 99%).
1.34

1

H-NMR (δ, ppm, CHLOROFORM-D):

(m, 4H), 1.49 (m, 1H), 1.61 (m, 2H), 1.79 (m, 1H), 2.33 (t, 2H), 2.47 (m,

1H), 2.69 (q, 1H), 3.02 (q, 1H), 5.09 (s, 2H), 7.09 (m, 3H), 7.25 (m, 2H), 7.32 (m,
4H), 7.38 (d, 2H), 7.89 (m, 1H), 8.40 (d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-
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D): 24.8, 27.1, 29.0, 33.1, 34.3, 38.6, 49.9, 66.4, 120.4, 124.7, 128.3, 128.4,
128.5, 128.8, 129.2, 136.2, 137.9, 149.4, 149.8, 173.0, 173.9; IR: 3304, 3221,
3035, 2931, 2858, 1734, 1602, 1443, 1173, 912, 752, 696 cm-1. HRMS (EI-TOF,
m/z): found [M+H] 431.2331, calc. for C27H31N2O3, 431.2335.

N8-hydroxy-N1-phenyl-2-(pyridin-4-ylmethyl)octanediamide

(22d).

To

a

solution of NH2OH∙HCl (536 mg, 7.67 mmol) in methanol (8 mL) was added KOH
(860 mg, 15.3 mmol) at 0 ˚C in an acid-washed 25mL round-bottom flask. After
stirring

for

20

ylmethyl)octanoate

min,

benzyl

8-oxo-8-(phenylamino)-7-(pyridine-4-

20d (330 mg, 0.767 mmol) was added and the mixture was

stirred for 8h at 0°C. The reaction mixture was quenched by adding 1mL of
distilled water and adjusting to pH 6 by adding concentrated aqueous
hydrochloric acid. The mixture was diluted with 8 mL of ethyl acetate, and
extracted with distilled water (equal volume to organic layer) at least 4 times. The
organic layer was dried over magnesium sulfate, filtered and concentrated. The
residue was purified by column chromatography (8% methanol/CH2Cl2 with 0.1%
Et3N) on acid-washed silica gel to give 22d (116 mg, 43%). 1H-NMR (δ, ppm,
METHANOL-D): 1.39 (m, 4H), 1.60 (m, 3H), 1.77 (m, 1H), 2.08 (t, 2H), 2.86 (m,
2H), 2.93-3.00 (m, 2H), 7.06 (t, 1H), 7.25 (t, 2H), 7.43 (d, 2H), 7.50 (d, 2H), 8.48
(d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-D): 25.4, 26.9, 28.8, 32.4, 32.8, 38.4,
120.3, 124.3, 125.8, 128.6, 138.1, 146.7, 153.8, 171.7, 174.1; IR: 3440, 3335,
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2866, 1720, 1641, 1528, 1442, 1133, 759, 660 cm-1; HRMS (EI-TOF, m/z): found
[M+H] 356.1966, calc. for C20H26N3O3, 356.1974. HPLC analytical purity analysis:
90%.

4.8

HDAC assay procedure
HDAC activity was measured using the Fluor de Lys® activity assay

(Biomol & Enzo) using the manufacturer’s protocol. Additional details were
shown in Section 3.6 of Chapter 3.
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Figure A.1. Dose response curve of C3-SAHA analogue 1a-e tested using the
HDAC activity from HeLa cells lysates from three independent trials with error
bars indicating standard error. In some case, the error bars are smaller than the
marker size. Data were fit to the sigmoidal curve using Kaleidograph 4.0
(Synergy Software) to determine the IC50. The insets were the results of the data
analysis. The data are reported in Table 2.1.
Table A.1 Inhibition of HDAC Activity of SAHA C3-Butyl with Hela Lysate
Concentration (M)
3.125 x 10-5
6.25 x 10-5
1.25 x 10-4
2.50 x 10-4
5.00 x 10-4
1.00 x 10-4

Trial 1
83
72
54
47
31
19

Trial 2
85
69
54
46
35
22

Trial 3
81
73
51
46
34
20

Mean
83
71
53
46
33
20

S.E
1
1
1
1
1
1

100
Table A.2 Inhibition of HDAC Activity of SAHA C3-Phenyl with Hela Lysate
Concentration (M)
1.00 x 10-6
1.5625 x 10-5
3.125 x 10-5
6.25 x 10-5
1.25 x 10-4
2.50 x 10-4
5.00 x 10-4

Trial 1
98
88
74
59
40
25
15

Trial 2
80
79
65
54
38
26
14

Trial 3
86
74
66
50
38
24
14

Mean
88
80
68
54
37
25
14

S.E
5
4
3
3
1
1
1

Table A.3 Inhibition of HDAC Activity of C3-SAHA Ethyl with Hela Lysate
Concentration (M)
1.00 x 10-6
7.8125 x 10-5
1.5625 x 10-5
3.125 x 10-5
6.25 x 10-5
1.25 x 10-4
-4
2.50 x 10

Trial 1
88
75
67
52
42
27
18

Trial 2
85
69
62
57
46
28
15

Trial 3
82
67
61
57
34
28
14

Mean
85
70
63
55
41
28
16

S.E
2
2
1
2
4
1
1

Table A.4 Inhibition of HDAC Activity of SAHA C3-Vinyl with Hela Lysate
Concentration (M)
1.00 x 10-6
3.906 x 10-6
7.8125 x 10-6
1.5625 x 10-5
3.125 x 10-5
-5
6.25 x 10

Trial 1
84
83
72
60
48
32

Trial 2
75
60
55
43
34
23

Trial 3
99
69
57
47
37
27

Mean
86
71
61
50
40
27

S.E
7
7
5
5
4
3

Table A.5 Inhibition of HDAC Activity of C3-SAHA Methyl with Hela Lysate
Concentration (M)
Trial 1
Trial 2
Trial 3
Mean
S.E
-9
1.00 x 10
95
93
77
88
4
6.25 x 10-8
85
75
72
77
4
-7
1.25 x 10
77
72
62
72
3
2.50 x 10-7
62
58
54
58
2
-7
5.00 x 10
45
46
43
44
1
-6
1.00 x 10
31
28
29
29
1
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Table A.6 Isoform Selective HDAC Inhibition of SAHA C3 Analogues
Compound

HDAC
Isoform
HDAC1

Trial 1

Trial 2

Mean

S.E

27

35

31

4

HDAC3
HDAC6

44
32

45
37

45
35

1
3

HDAC1

44

47

46

2

HDAC3
HDAC6

53
73

62
75

57
74

5
1

HDAC1

38

39

39

1

HDAC3
HDAC6

71
17

95
18

83
18

12
1

C3-Vinyl
(32 µM)

HDAC1
HDAC3
HDAC6

23
47
26

26
51
28

25
49
27

2
2
1

C3-Butyll
(32 µM)

HDAC1
HDAC3
HDAC6

33
52
22

33
52
25

33
52
24

0
0
2

C3-Phenyl
(32 µM)

HDAC1
HDAC3
HDAC6

42
50
24

48
51
27

45
51
26

3
1
2

SAHA
(125 nM)
C3-Methyl
(375 nM)
C3-Ethyl
(32 µM)

Deacetylase activity of HDAC1, HDAC3 and HDAC6 was determined with SAHA
and with SAHA C3 analogs at given concentration using an in vitro fluorescence
assay as described. The background fluorescence activity (No enzyme added)
was subtracted and the percentage deacetylase activity was calculated with
compared to the No small molecule treated (100%). Percentage deacetylase
activity of each independent trial, mean percentage deacetylase activity and
standard error (S.E) are shown.
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Figure A.2. Dose response curves of SAHA tested against HDAC1, HDAC3, and
HDAC6 from three independent trials with error bars indicating standard error. In
some cases, the error bars are smaller than the marker size. The data is
reported in the manuscript in Table 2.2.

103

Figure A.3. Dose response curves of the C3- SAHA ethyl analogue 1c tested
against HDAC1, HDAC3, and HDAC6 from three independent trials with error
bars indicating standard error. In some cases, the error bars are smaller than the
marker size. The data is reported in the manuscript in Table 2.2.
Table A.7 Inhibition of HDAC1 Activity by SAHA
Concentration (M)
3.125 x 10-8
6.25 x 10-8
1.25 x 10-7
2.50 x 10-7

Trial 1
68
55
48
37

Trial 2
91
62
27
40

Trial 3
82
57
37
25

Mean
80
58
37
34

S.E
7
2
6
5

Mean
80
73
56
34

S.E
4
2
5
4

Table A.8 Inhibition of HDAC3 Activity by SAHA
Concentration (M)
3.125 x 10-8
6.25 x 10-8
1.25 x 10-7
2.50 x 10-7

Trial 1
88
76
63
27

Trial 2
78
74
45
39

Trial 3
74
70
44
37
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Table A.9 Inhibition of HDAC6 Activity by SAHA
Concentration (M)
3.125 x 10-8
6.25 x 10-8
1.25 x 10-7
2.50 x 10-7

Trial 1
66
64
37
13

Trial 2
76
62
28
12

Trial 3
73
60
32
9

Mean
72
62
32
11

S.E
3
1
2
1

Table A.10 Inhibition of HDAC1 Activity by SAHA C3-Ethyl
Concentration (M)
1.00 x 10-6
7.8125 x 10-6
1.5625 x 10-5
3.125 x 10-5

Trial 1
102
83
58
39

Trial 2
89
94
65
38

Trial 3
ND
86
51
ND

Mean
96
88
58
39

S.E
9
6
7
1

Table A.11 Inhibition of HDAC3 Activity by SAHA C3-Ethyl
Concentration (M)
3.125 x 10-5
62.50 x 10-5
1.25 x 10-4
2.50x 10-5

Trial 1
95
58
46
20

Trial 2
71
57
35
21

Trial 3
ND
66
53
25

Mean
83
60
45
22

S.E
12
3
5
2

Table A.12 Inhibition of HDAC6 Activity by SAHA C3-Ethyl
Concentration (M)
-6
1.000 x 10
3.906 x 10-6
7.812 x 10-6
1.562 x 10-5
3.125 x 10-5

Trial 1
81
69
52
38
17

Trial 2
76
65
58
40
18

Trial 3
78
64
51
38
ND

Mean
78
66
54
39
18

S.E
1
2
2
1
1
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B.1 5-Hydroxy-N-phenylpentanamide (3)
B.1.1 1H NMR

B.1.2 13C NMR

106
B.1.3 IR

107
B.1.4 HRMS

B.2 6-Oxo-6-(phenylamino)hexanal (4)
B.2.1 1H NMR

108
B.2.2 13C NMR

109
B.2.3 IR

110
B.2.4 HRMS

B.3 8-Oxo-8-(phenylamino)-oct-2-enoate (5)
B.3.1 1H NMR (E)

111
B.3.2 1H NMR (Z)

B.3.3 13C NMR

112
B.3.4 IR

113
B.3.5 HRMS

B.4 8-Oxo-8-(phenylamino)-3-n-butyloctanoate (6a)
B.4.1 1H NMR

114
B.4.2 13C NMR

115
B.4.3 IR

116
B.4.4 HRMS

B.5 8-Oxo-8-(phenylamino)-3-phenyloctanoate (6b)
B.5.1 1H NMR

117
B.5.2 13C NMR

118
B.5.3 IR

119
B.5.4 HRMS

B.6 8-Oxo-8-(phenylamino)-3-ethyloctanoate (6c)
B.6.1 1H NMR

120
B.6.2 13C NMR

121
B.6.3 IR

122
B.6.4 HRMS

B.7 8-Oxo-8-(phenylamino)-3-vinyloctanoate (6d)
B.7.1 1H NMR

123
B.7.2 13C NMR

124
B.7.3 IR

125
B.7.4 HRMS

B.8 8-Oxo-8-(phenylamino)-3-methyloctanoate (6e)
B.8.1 1H NMR

126
B.8.2 13C NMR

B.8.3 IR

127
B.8.1 HRMS

B.9 3-n-Butyl-N1-hydroxyl-N8-phenyloctanoic acid (7)
B.9.1 1H NMR

128
B.9.2 13C NMR

129
B.9.3 IR

B.9.4 HRMS

130
B.10 3-n-Butyl-N1-benzyloxy-N8-phenyloctanediamide (8)
B.10.1 1H NMR

131
B.10.2 13C NMR

132
B.10.3 IR

133
B.10.4 HRMS

B.11 3-n-Butyl-N1-hydroxyl-N8-phenyloctandiamide (1a)
B.11.1 1H NMR

134
B.11.2 13C NMR

135
B.11.3 IR

B.11.4 HRMS

136
B.11.5 HPLC

137
B.12 3-Phenyl-N1-hydroxyl-N8-phenyloctandiamide (1b)
B.12.1 1H NMR

B.12.2 13C NMR

138
B.12.3 IR

139
B.12.4 HRMS

B.12.5 HPLC

140
B.13 3-Ethyl-N1-hydroxyl-N8-phenyloctandiamide (1c)
B.13.1 1H NMR

B.13.2 13C NMR

141
B.13.3 IR

142
B.13.4 HRMS

4.668

B.13.5 HPLC
0.90
0.80
0.70

AU

0.60
0.50
0.40
0.30
0.20
0.10
0.00
0.00

2.00

RT

4.00

Area

% Area

6.00

Height

1 4.668 7510006 100.00 924974

8.00

10.00
Minutes

12.00

14.00

16.00

18.00

20.00

143
B.14 3-Vinyl-N1-hydroxyl-N8-phenyloctandiamide (1d)
B.14.1 1H NMR

B.14.2 13C NMR

144
B.14.3 IR

145
B.14.4 HRMS

10.156

B.14.5 HPLC

2.50

1.50

1.00

0.50

9.489
9.821

AU

2.00

0.00
0.00

2.00

RT

4.00

Area

6.00

% Area

8.00

Height

1

9.489

888985

3.29

135811

2

9.821

803374

2.97

134069

3 10.156 25352757

93.74 2759849

10.00
Minutes

12.00

14.00

16.00

18.00

20.00

146
B.15 3-Methyl-N1-hydroxyl-N8-phenyloctandiamide (1e)
B.15.1 1H NMR

B.15.2 13C NMR

147
B.15.3 IR

148
B.15.4 HRMS

B.15.5 HPLC
13.475

3.00

2.50

1.50

1.00

11.950

AU

2.00

0.50

0.00
0.00

2.00

Peak Name
1 Peak2

4.00

RT

6.00

Area

8.00

% Area

10.00
Minutes

Height

9.489

2 Peak3

9.821

3 Peak4

10.156

4 Peak1

10.871

5

11.950

6

13.475 57777809

1469677

2.48

129416

97.52 3069522

12.00

14.00

16.00

18.00

20.00
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Table C.1. Percentage HDAC activity after incubation of SAHA with Hela Lysate
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
(M)
Error (S.E.)
-8
3.125 x 10
75
75
ND
75
0
6.25 x 10-8
63
56
51
57
3
-7
1.25 x 10
44
35
40
40
3
2.5 x 10-7
31
21
26
26
3
-7
5.0 x 10
20
16
15
17
2

Figure C.1. Dose response curve of SAHA tested using the HDAC activity from
HeLa cells lysates from three independent trials In some case, the error bar is
smaller than the marker size. Data were fit to the sigmoidal curve using
Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The insets were the
results of the data analysis. The data are reported in Table 3.1.
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Table C.2. Percentage HDAC activity after incubation of MS-275 with Hela
Lysate
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard Error
(M)
(S.E.)
1.95 x 10-6
58
59
58
58
0.3
-6
3.91 x 10
44
47
49
47
1
7.81 x 10-6
32
35
33
33
1
-5
1.56 x 10
27
27
26
27
0.3
-5
6.25 x 10
9
12
11
11
1

Figure C.2. Dose response curve of MS-275 tested using the HDAC activity from
HeLa cells lysates from three independent trials. In some cases, the error bars
are smaller than the marker size. Data were fit to the sigmoidal curve using
Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The insets were the
results of the data analysis. The data are reported in Table 3.1.
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Table C.3. Percentage HDAC activity after incubation of C6-SAHA methyl
analogue 14a with Hela Lysate
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard Error
(M)
(S.E.)
-8
6.25 x 10
104
72
102
92
10
1.25 x 10-7
94
50
85
76
13
-7
2.5 x 10
66
51
79
65
8
-7
5.0 x 10
30
32
40
34
3
1.0 x 10-6
24
20
22
22
1

Figure C.3. Dose response curve of C6-SAHA methyl analogue 14a tested using
the HDAC activity from HeLa cells lysates from three independent trials. In some
case, the error bar is smaller than the marker size. Data were fit to the sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The
insets were the results of the data analysis. The data are reported in Table 3.1.
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Table C.4. Percentage HDAC activity after incubation of C6-SAHA phenyl
analogue 14b with Hela Lysate
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
6.25 x 10-8
87
87
82
85
1
1.25 x 10-7
75
73
75
74
0.7
2.5 x 10-7
59
41
54
51
5
-7
5.0 x 10
45
47
51
47
1
1.0 x 10-6
27
23
20
23
2

Figure C.4. Dose response curve of C6-SAHA phenyl analogue 14b tested
using the HDAC activity from HeLa cells lysates from three independent trials
with error bars indicating standard error. In some case, the error bar is smaller
than the marker size. Data were fit to the sigmoidal curve using Kaleidograph 4.0
(Synergy Software) to determine the IC50. The insets were the results of the data
analysis. The data are reported in Table 3.1.
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Table C.5. Percentage HDAC activity after incubation of C6-SAHA t-butyl
analogue 14c with Hela Lysate
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
1.11 x 10-7
94
99
114
102
6
-7
3.33 x 10
65
87
103
85
11
-6
1.0 x 10
55
58
71
61
4
-6
3.0 x 10
40
37
41
39
1
-6
9.0 x 10
28
20
18
22
3

Figure C.5. Dose response curve of C6-SAHA t-butyl analogue 14c tested using
the HDAC activity from HeLa cells lysates from three independent trials. In some
case, the error bar is smaller than the marker size. Data were fit to the sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The
insets were the results of the data analysis. The data are reported in Table 3.1.
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Table C.6. Percentage HDAC activity after incubation of C6-SAHA 2-ethylhexyl
analogue 14d with Hela Lysate
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
1.11 x 10-7
93
69
78
80
7
-7
3.33 x 10
62
54
55
57
2
-6
1.0 x 10
42
22
38
34
6
3.0 x 10-6
12
8
13
11
1
-6
9.0 x 10
4
2
2
2.7
0.7

Figure C.6. Dose response curve of C6-SAHA 2-ethylhexyl analogue 14d tested
using the HDAC activity from HeLa cells lysates from three independent trials
with error bars indicating standard error. In some case, the error bar is smaller
than the marker size. Data were fit to the sigmoidal curve using Kaleidograph 4.0
(Synergy Software) to determine the IC50. The insets were the results of the data
analysis. The data are reported in Table 3.1.
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Table C.7. Deacetylase activity percentage remaining after incubation of
HDAC1, HDAC3, or HDAC6 with SAHA or the C6-SAHA analogues 14a-e.
Compound
HDAC
Trial 1
Trial 2
Mean
S.E.
Isoform
HDAC1
30
35
32
2
SAHA
HDAC3
44
45
44
1
(125 nM)
HDAC6
32
36
34
2
HDAC1

35

42

38

3

HDAC3
HDAC6

32
61

33
58

32
59

0.5
1

HDAC1

57

56

56

0.5

HDAC3
HDAC6

68
61

67
58

67
59

0.5
1

C6-t-Butyl
(2 µM)

HDAC1
HDAC3
HDAC6

44
79
56

46
82
55

45
80
55

1
1
0.5

C6-2-Ethylhexyl
(500 nM)

HDAC1
HDAC3
HDAC6

77
51
91

73
54
95

75
52
93

2
1
2

C6-Isopropyl
(µM)

HDAC1
HDAC3
HDAC6

42
50
24

48
51
27

45
51
26

3
1
2

C6-Methyl
(500 nM)
C6-Phenyl
(500 nM)

Deacetylase activity of HDAC1, HDAC3 and HDAC6 was determined with SAHA
and with C6-SAHA analogues at given concentration using an in vitro
fluorescence assay as described (Section 3.6). The fluorescence activity of
background (No enzyme added) was subtracted from the no small molecule
treated (positive control) and the percentage of the deacetylase activity was set
to 100%. Deacetylase activity percentage of each independent trial, mean
percentage of deacetylase activity, and standard error (S.E.) are illustrated. The
data are reported in the manuscript in Figure 3.2.
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Table C.8. HDAC1 activity percentage after incubation of SAHA.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
(M)
(S.E.)
-8
3.125 x 10
68
91
82
80
7
-8
6.25 x 10
55
62
57
58
2
1.25 x 10-7
48
27
37
37
6
-7
2.50 x 10
37
40
25
34
5

Error

Figure C.7. Dose response curve of SAHA tested using the HDAC1 activity from
three independent trials with error bars indicating standard error. Data were fit to
the sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the
IC50. The insets were the results of the data analysis. The data are reported in
Table 3.2.
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Table C.9. HDAC3 activity percentage after incubation of SAHA.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
(M)
(S.E.)
3.125 x 10-8
88
78
74
80
4
-8
6.25 x 10
76
74
70
73
2
-7
1.25 x 10
63
45
44
56
5
2.50 x 10-7
27
39
37
34
4

Error

Figure C.8. Dose response curve of SAHA tested using the HDAC3 activity from
three independent trials with error bars indicating standard error. Data were fit to
the sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the
IC50. The insets were the results of the data analysis. The data are reported in
Table 3.2.
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Table C.10. HDAC6 activity percentage after incubation of SAHA.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
(M)
(S.E.)
-8
3.125 x 10
66
76
73
72
3
6.25 x 10-8
64
62
60
62
1
-7
1.25 x 10
37
28
32
32
2
-7
2.50 x 10
13
12
9
11
1

Error

Figure C.9. Dose response curve of SAHA tested using the HDAC6 activity from
three independent trials with error bars indicating standard error. In some case,
the error bars are smaller than the marker size. Data were fit to the sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The
insets were the results of the data analysis. The data are reported in Table 3.2.
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Table C.11. HDAC1 activity percentage after incubation of C6-SAHA t-butyl
analogue 14c.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
2.50 x 10-7
102
92
82
92
5
-7
5.00 x 10
86
85
80
84
1
-6
1.00 x 10
68
44
35
49
9
3.125 x 10-5
7
1
1
3
2

Figure C.10. Dose response curve of C6-SAHA t-butyl analogue 14c tested
using the HDAC1 activity from three independent trials with error bars indicating
standard error. Data were fit to the sigmoidal curve using Kaleidograph 4.0
(Synergy Software) to determine the IC50. The insets were the results of the data
analysis. The data are reported in Table 3.2.
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Table C.12. HDAC3 activity percentage after incubation of C6-SAHA t-butyl
analogue 14c.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
1.00 x 10-6
87
85
81
84
1
-6
4.00 x 10
76
63
52
64
6
-5
1.5625 x 10
21
20
13
18
2
3.125 x 10-5
7
6
6
6
-

Figure C.11. Dose response curve of C6-SAHA t-butyl analogue 14c tested
using the HDAC3 activity from three independent trials. In some case, the error
bar is smaller than the marker size. Data were fit to the sigmoidal curve using
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets were the
results of the data analysis. The data are reported in Table 3.2.
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Table C.13. HDAC6 activity percentage after incubation of C6-SAHA t-butyl
analogue 14c.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
5.00 x 10-7
98
90
88
92
3
-6
1.00 x 10
89
82
86
85
2
2.00 x 10-6
48
35
48
44
4
-6
4.00 x 10
45
29
45
40
5

Figure C.12. Dose response curve of C6-SAHA t-butyl analogue 14c tested
using the HDAC6 activity from three independent trials with error bars indicating
standard error. Data were fit to the sigmoidal curve using Kaleidograph 4.0
(Synergy Software) to determine the IC50. The insets were the results of the data
analysis. The data are reported in Table 3.2.
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APPENDIX D. SUPPLEMENTARY INFORMATION FOR C6-SAHA LIBRARY
D.1 Methyl 6-hydroxyhexanoate (9)
D.1.1 1H NMR

D.1.2 13C NMR

163
D.1.3 IR

164
D.1.4 HRMS

165
D.2 1-Benzyl 8-methyl oct-2-enedioate (11)
D.2.1 1H NMR

D.2.2 13C NMR

166
D.2.3 IR

167
D.2.4 HRMS

D.3 1-Benzyl 8-methyl 3-methyloctanedioate (12a)
D.3.1 1H NMR

168
D.3.2 13C NMR

D.3.3 HRMS

169
D.4 1-Benzyl 8-methyl 3-(tert-butyl)octanedioate (12c)
D.4.1 1H NMR

170
D.4.2 13C NMR

171
D.4.3 IR

172
D.4.4 LRMS [M+Li]

D.5 1-Benzyl 8-methyl 3-(2-ethylhexyl)octanedioate (12d)
D.5.1 1H NMR

173
D.5.2 13C NMR

174
D.5.3 IR

175
D.5.4 LRMS [M+K], [M+Li], and [M+Na]

D.6.1 1-Benzyl 8-methyl 3-isopropyloctanedioate (12e)
D.6.1 1H NMR

176
D.6.2 13C NMR

177
D.6.3 IR

178
D.6.4 HRMS

D.7 Methyl 6-methyl-8-oxo-8-(phenylamino)octanoate (13a)
D.7.1 1H NMR

179
D.7.2 13C NMR

180
D.7.3 IR

181
D.7.4 HRMS

D.8 Methyl 6-(tert-butyl)-8-oxo-8-(phenylamino)octanoate (13c)
D.8.1 1H NMR

182
D.8.2 13C NMR

D.8.3 IR

183
D.8.4 HRMS

D.9 Methyl 8-ethyl-6-(2-oxo-2-(phenylamino)ethyl)dodecanoate (13d)
D.9.1 1H NMR

184
D.9.2 13C NMR

185
D.9.3 IR

186
D.9.4 LRMS [M+Li], [M+Na], and [M+K]

D.10 Methyl 6-isopropyl-8-oxo-8-(phenylamino)octanoate (13e)
D.10.1 1H NMR

187
D.10.2

13

C NMR

188
D.10.3 IR

189
D.10.4 HRMS

D.11 N8-Hydroxyl-3-methyl-N1-phenyloctanediamide (14a)
D.11.1 1H NMR

190
D.11.2 13C NMR

191
D.11.3 IR

192
D.11.4 HRMS

D. 12 N8-Hydroxyl-N8, 3-diphenyloctanediamide (14b)
D.12.1 1H NMR

193
D.12.2 13C NMR

194
D.12.3 IR

195
D.12.4 HRMS

D.13 3-(tert-Butyl)-N8-hydroxyl-N1-phenyloctanediamide (14c)
D.13.1 1H NMR

196
D.13.2 13C NMR

197
D.13.3 IR

198
D.13.4 HRMS

D.14 3-(2-Ethylhexyl)-N8-hydroxyl-N1-phenyloctanediamide (14d)
D.14.1 1H NMR

199
D.14.2 13C NMR

200
D.14.3 IR

D.14.4 HRMS
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APPENDIX E. DOSE RESPONSE GRAPHS AND DATA FOR C7-SAHA
LIBRARY
Table E.1. Percentage HDAC activity after incubation of SAHA with Hela Lysate
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
3.125 x 10-8
75
75
76
75
0
6.25 x 10-8
63
56
51
57
3
-7
1.25 x 10
44
35
40
40
3
2.5 x 10-7
31
21
26
26
3
-7
5.0 x 10
20
16
15
17
2

Figure E.1. Dose response curve of SAHA tested using the HDAC activity from
HeLa cells lysates from three independent trials. In some case, the error bar is
smaller than the marker size. Data were fit to the sigmoidal curve using
Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The insets were the
results of the data analysis. The data are reported in Table 4.1.
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Table E.2. Percentage HDAC activity after incubation of C7-SAHA pyridyl
analogue 22d with Hela Lysate
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
1.11 x 10-7
70
70
86
75
5
-7
3.33 x 10
63
66
49
59
5
-6
1.00 x 10
45
24
31
33
6
3.00 x 10-6
18
5
18
14
4
-6
9.00 x 10
8
-2
24
3
3

Figure E.2. Dose response curve of C7-SAHA pyridyl analogue 22d tested
using the HDAC activity from HeLa cells lysates from three independent trials.
Data were fit to the sigmoidal curve using Kaleidograph 4.0 (Synergy Software)
to determine the IC50. The insets are the results of the data analysis. The data
were reported in Table 4.2.
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Table E.3. Percentage HDAC activity after
methylanthracene analogue 22f with Hela Lysate.
Concentration (M) Trial 1
Trial 2
Trial 3
4.10 x 10-9
81
76
75
-8
1.23 x 10
47
60
61
-8
3.70 x 10
33
38
49
1.11 x 10-7
27
15
23
-7
3.33 x 10
10
12
13
1.00 x 10-6
7
5
8

incubation
Mean
77
56
40
22
12
7

of

C7-SAHA

S.E.
2
4
4
3
1
1

Figure E.3. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f
tested using the HDAC activity from HeLa cells lysates from three independent
trials. In some case, the error bars are smaller than the marker size. The insets
were the results of the data analysis. The data are reported in Table 4.2.
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Table E.4. Percentage HDAC activity after incubation
methyltetrahydro-anthracene analogue 22g with Hela Lysate.
Concentration (M) Trial 1
Trial 2
Trial 3
Mean
1.00 x 10-8
92
124
92
102
-8
5.00 x 10
38
68
76
60
-7
2.50 x 10
27
27
30
28
1.25 x 10-6
11
25
15
17
-6
6.25 x 10
-2
2
0.5
0

of

C7-SAHA

S.E.
10
11
1
4
1

Figure E.4. Dose response curve of C7-SAHA tetrahydroanthracenylmethyl
analogue 22g tested using the HDAC activity from HeLa cells lysates from
three independent trials with error bars indicating standard error. In some case,
the error bars are smaller than the marker size. Data were fit to the sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The
insets were the results of the data analysis. The data are reported in Table 4.2.
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Table E.5. Deacetylase activity percentage remaining after incubation of
HDAC1, HDAC3, or HDAC6 with SAHA and the C7-SAHA analogues 22a-g.
Compound
HDAC
Trial 1
Trial 2
Mean
S.E.
Isoform
HDAC1
30
35
32
2
SAHA
HDAC3
44
45
44
1
(125 nM)
HDAC6
32
36
34
2
C7-Methyl
(100 nM)
C7-Benzyl
(100 nM)
C7-Pyridyl
(500 nM)
C7-Tetrahydroanthracene
(100 nM)
C7-Biphenyl
(100 nM)
C7-Naphthyl
(10 nM)

C7-Anthracene
(500 nM)

HDAC1

38

52

45

7

HDAC3
HDAC6

27
21

57
35

42
28

10
7

HDAC1

66

87

76

10

HDAC3
HDAC6

54
55

88
66

71
60

11
5

HDAC1
HDAC3
HDAC6

44
101
62

68
92
55

56
97
59

10
4
3

HDAC1
HDAC3
HDAC6

64
47
76

66
60
84

65
53
80

1
6
4

HDAC1
HDAC3
HDAC6

91
91
71

114
96
82

102
93
76

10
2
5

HDAC1

103

121

112

9

HDAC3

55

60

57

2

HDAC6

82

104

93

10

HDAC1

42

47

44

2

HDAC3

89

90

89

0

HDAC6

50

56

53

3

Deacetylase activity of HDAC1, HDAC3 and HDAC6 was determined with SAHA
and with C7-SAHA analogues at given concentration using an in vitro
fluorescence assay as described (Section 3.6). The fluorescence activity of
background (No enzyme added) was subtracted from the no small molecule
treated (positive control) and the percentage of the deacetylase activity was set

206
to 100%. Deacetylase activity percentage of each independent trial, mean
percentage of deacetylase activity, and standard error (S.E.) are illustrated. The
data are reported in the manuscript in Figure 4.2.
Table E.6. HDAC1 activity percentage after incubation of SAHA.
Concentration Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
3.125 x 10-8
68
91
82
80
7
-8
6.25 x 10
55
62
57
58
2
1.25 x 10-7
48
27
37
37
6
-7
2.50 x 10
37
40
25
34
5

Figure E.5. Dose response curve of SAHA tested using the HDAC1 activity from
three independent trials with error bars indicating standard error. In some case,
the error bar is smaller than the marker size. Data were fit to the sigmoidal curve
using Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The insets
were the results of the data analysis. The data are reported in Table 4.3.
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Table E.7. HDAC3 activity percentage after incubation of SAHA.
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
(M)
(S.E.)
-8
3.125 x 10
88
78
74
80
4
6.25 x 10-8
76
74
70
73
2
-7
1.25 x 10
63
45
44
56
5
-7
2.50 x 10
27
39
37
34
4

Error

Figure E.6. Dose response curve of SAHA tested using the HDAC3 activity from
three independent trials with error bars indicating standard error. In some case,
the error bar is smaller than the marker size. Data were fit to the sigmoidal curve
using Kaleidograph 4.0 (Synergy Software) to determine the IC 50. The insets
were the results of the data analysis. The data are reported in Table 4.3.
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Table E.8. HDAC6 activity percentage after incubation of SAHA.
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
(M)
(S.E.)
3.125 x 10-8
66
76
73
72
3
-8
6.25 x 10
64
62
60
62
1
-7
1.25 x 10
37
28
32
32
2
-7
2.50 x 10
13
12
9
11
1

Error

Figure E.7. Dose response curve of SAHA tested using the HDAC6 activity from
three independent trials with error bars indicating standard error. In some case,
the error bars are smaller than the marker size. Data were fit to the sigmoidal
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The
insets were the results of the data analysis. The data are reported in Table 4.3.
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Table E.9. HDAC1 activity percentage after incubation of C7-SAHA
anthracenylmethyl 22f.
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
1.11 x 10-7
103
96
86
96
4
-7
3.33 x 10
33
42
43
39
3
-6
1.00 x 10
17
16
17
17
0

Figure E.8. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f
tested using the HDAC1 activity from three independent trials with error bars
indicating standard error. Data were fit to the sigmoidal curve using Kaleidograph
4.0 (Synergy Software) to determine the IC50. The insets were the results of the
data analysis. The data are reported in Table 4.3.
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Table E.10. HDAC3 activity percentage after incubation of C7-SAHA
anthracenylmethyl 22f.
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
3.33 x 10-7
84
87
86
86
1
1.00 x 10-6
51
57
70
59
5
-6
3.00 x 10
13
23
27
21
4

Figure E.9. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f
tested using the HDAC3 activity from three independent trials with error bars
indicating standard error. In some case, the error bar is smaller than the marker
size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 (Synergy
Software) to determine the IC50. The insets are the results of the data analysis.
The data were reported in Table 4.3.
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Table E.11. HDAC6 activity percentage after incubation of C7-SAHA
anthracenylmethyl 22f.
Concentration
Trial 1
Trial 2
Trial 3
Mean
Standard
Error
(M)
(S.E.)
1.00 x 10-7
85
84
63
77
7
3.00 x 10-7
52
53
56
54
1
-7
9.00 x 10
37
36
44
39
2

Figure E.10. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f
tested using the HDAC6 activity from three independent trials with error bars
indicating standard error. In some case, the error bar is smaller than the marker
size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 (Synergy
Software) to determine the IC50. The insets were the results of the data analysis.
The data were reported in Table 4.3.
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APPENDIX F. SUPPLEMENTARY INFORMATION FOR C7-SAHA LIBRARY
F.1. 1,1-Dibenzyl 6-methyl hexane-1, 1, 6-tricarboxylate (24).
F.1.1. 1H NMR

F.1.2. 13C NMR

213
F.1.3. IR

214
F.1.4. HRMS

F.2. 6, 6-Dibenzyl 1-methyl 7-(pyridine-4-yl)heptane-1, 6, 6-tricarboxylate (25).
F.2.1. 1H NMR

215
F.2.2. 13C NMR

216
F.2.3. IR

217
F.2.4. HRMS

F.3. Benzyl 6-bromohexanoate (16).
F.3.1. 1H NMR

218
F.3.2. 13C NMR

219
F.3.3. IR

220
F.3.4. HRMS

F.4. 6-Benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate (17).
1
F.4.1. H NMR

221
F.4.2. 13C NMR

222
F.4.3. IR

223
F.4.4. LRMS

F.5. 1-Benzyl 6,6-di-tert-butyl 7-(pyridine-4-yl)heptane-1,6,6-tricaboxylate (18d).
F.5.1. 1H NMR

224
F.5.2. 13C NMR

225
F.5.3. IR

226
F.5.4. HRMS

F.6. Benzyl 8-oxo-8-(phenylamino)-7-(pyridine-4-ylmethyl)octanoate
F.6.1. 1H NMR

(20d).

227
F.6.2. 13C NMR

F.6.3. IR

228
F.6.4. HRMS

F.7. N8-hydroxy-N1-phenyl-2-(pyridin-4-ylmethyl)octanediamide (22d)
F.7.1. 1H NMR

229
F.7.2. 13C NMR

230
F.7.3. IR

231
F.7.4. HRMS

F.7.4. HPLC

232

REFERENCES
1.

Moving AHEAD with an international human epigenome project. Nature 2008,

454 (7205), 711-5.
2.

Yoo, C. B.; Jones, P. A., Epigenetic therapy of cancer: past, present and future.

Nat Rev Drug Discov 2006, 5 (1), 37-50.
3.

Gregoretti, I. V.; Lee, Y. M.; Goodson, H. V., Molecular evolution of the histone

deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004,
338 (1), 17-31.
4.

Grozinger, C. M.; Schreiber, S. L., Deacetylase enzymes: biological functions

and the use of small-molecule inhibitors. Chem Biol 2002, 9 (1), 3-16.
5.

Khabele, D.; Son, D. S.; Parl, A. K.; Goldberg, G. L.; Augenlicht, L. H.;

Mariadason, J. M.; Rice, V. M., Drug-induced inactivation or gene silencing of class I
histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Cancer Biol Ther 2007, 6 (5), 795-801.
6.

Song, J.; Noh, J. H.; Lee, J. H.; Eun, J. W.; Ahn, Y. M.; Kim, S. Y.; Lee, S. H.;

Park, W. S.; Yoo, N. J.; Lee, J. Y.; Nam, S. W., Increased expression of histone
deacetylase 2 is found in human gastric cancer. APMIS 2005, 113 (4), 264-8.
7.

Bartling, B.; Hofmann, H. S.; Boettger, T.; Hansen, G.; Burdach, S.; Silber, R. E.;

Simm, A., Comparative application of antibody and gene array for expression profiling in
human squamous cell lung carcinoma. Lung Cancer 2005, 49 (2), 145-54.
8.

Krennhrubec, K.; Marshall, B. L.; Hedglin, M.; Verdin, E.; Ulrich, S. M., Design

and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg
Med Chem Lett 2007, 17 (10), 2874-8.

233

9.

Saji, S.; Kawakami, M.; Hayashi, S.; Yoshida, N.; Hirose, M.; Horiguchi, S. I.;

Itoh, A.; Funata, N.; Schreiber, S. L.; Yoshida, M.; Toi, M., Significance of HDAC6
regulation via estrogen signaling for cell motility and prognosis in estrogen receptorpositive breast cancer. Oncogene 2005, 24 (28), 4531-4539.
10.

(a) de Ruijter, A. J.; van Gennip, A. H.; Caron, H. N.; Kemp, S.; van Kuilenburg,

A. B., Histone deacetylases (HDACs): characterization of the classical HDAC family.
Biochem J 2003, 370 (Pt 3), 737-49; (b) Fischer, D. D.; Cai, R.; Bhatia, U.; Asselbergs,
F. A.; Song, C.; Terry, R.; Trogani, N.; Widmer, R.; Atadja, P.; Cohen, D., Isolation and
characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem 2002,
277 (8), 6656-66.
11.

(a) Kramer, O. H.; Gottlicher, M.; Heinzel, T., Histone deacetylase as a

therapeutic target. Trends in endocrinology and metabolism: TEM 2001, 12 (7), 294300; (b) Garber, K., HDAC inhibitors overcome first hurdle. Nat Biotechnol 2007, 25 (1),
17-9.
12.

Grant, S.; Easley, C.; Kirkpatrick, P., Vorinostat. Nat Rev Drug Discov 2007, 6

(1), 21-2.
13.

Robey, R. W.; Chakraborty, A. R.; Basseville, A.; Luchenko, V.; Bahr, J.; Zhan,

Z.; Bates, S. E., Histone deacetylase inhibitors: emerging mechanisms of resistance.
Mol Pharm 2011, 8 (6), 2021-31.
14.

Bressi, J. C.; Jennings, A. J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.;

O'Connell, S.; Grimshaw, C. E.; Navre, M.; Gangloff, A. R., Exploration of the HDAC2
foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg
Med Chem Lett 2010, 20 (10), 3142-5.

234

15.

Watson, P. J.; Fairall, L.; Santos, G. M.; Schwabe, J. W., Structure of HDAC3

bound to co-repressor and inositol tetraphosphate. Nature 2012, 481 (7381), 335-40.
16.

Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Cirillo, A.; Scarpelli, R.; Ferrigno,

F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkuhler, C.; Gallinari, P.; Carfi,
A., Structural and functional analysis of the human HDAC4 catalytic domain reveals a
regulatory structural zinc-binding domain. J Biol Chem 2008, 283 (39), 26694-704.
17.

(a) Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.;

Luong, C.; Arvai, A.; Buggy, J. J.; Chi, E.; Tang, J.; Sang, B. C.; Verner, E.; Wynands,
R.; Leahy, E. M.; Dougan, D. R.; Snell, G.; Navre, M.; Knuth, M. W.; Swanson, R. V.;
McRee, D. E.; Tari, L. W., Structural snapshots of human HDAC8 provide insights into
the class I histone deacetylases. Structure 2004, 12 (7), 1325-34; (b) Vannini, A.;
Volpari, C.; Filocamo, G.; Casavola, E. C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.;
Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S., Crystal
structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8,
complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of
Sciences of the United States of America 2004, 101 (42), 15064-9.
18.

Marks, P.; Rifkind, R. A.; Richon, V. M.; Breslow, R.; Miller, T.; Kelly, W. K.,

Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1 (3),
194-202.
19.

O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.;

MacGregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; Zelenetz, A.
D.; Frankel, S.; Richon, V.; Marks, P.; Kelly, W. K., Clinical experience with intravenous
and oral formulations of the novel histone deacetylase inhibitor suberoylanilide

235

hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol
2006, 24 (1), 166-73.
20.

Bieliauskas, A. V.; Pflum, M. K. H., Isoform-selective histone deacetylase

inhibitors. Chemical Society Reviews 2008, 37 (7), 1402-1413.
21.

(a) Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.;

Yamashita, T.; Nakanishi, O., Synthesis and histone deacetylase inhibitory activity of
new benzamide derivatives. J Med Chem 1999, 42 (15), 3001-3; (b) Dai, Y.; Guo, Y.;
Guo, J.; Pease, L. J.; Li, J.; Marcotte, P. A.; Glaser, K. B.; Tapang, P.; Albert, D. H.;
Richardson, P. L.; Davidsen, S. K.; Michaelides, M. R., Indole amide hydroxamic acids
as potent inhibitors of histone deacetylases. Bioorg Med Chem Lett 2003, 13 (11),
1897-901; (c) Mai, A.; Massa, S.; Pezzi, R.; Rotili, D.; Loidl, P.; Brosch, G., Discovery of
(aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone
deacetylase homologue HD1-A. J Med Chem 2003, 46 (23), 4826-9.
22.

(a) Bouchain, G.; Delorme, D., Novel hydroxamate and anilide derivatives as

potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr
Med Chem 2003, 10 (22), 2359-72; (b) Nagaoka, Y.; Maeda, T.; Kawai, Y.; Nakashima,
D.; Oikawa, T.; Shimoke, K.; Ikeuchi, T.; Kuwajima, H.; Uesato, S., Synthesis and
cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic
hydroxamates and 2-aminobenzamide-containing derivatives. Eur J Med Chem 2006,
41 (6), 697-708; (c) Uesato, S.; Kitagawa, M.; Nagaoka, Y.; Maeda, T.; Kuwajima, H.;
Yamori, T., Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a
terminal bicyclic aryl group. Bioorg Med Chem Lett 2002, 12 (10), 1347-9; (d) Jung, M.;
Brosch, G.; Kolle, D.; Scherf, H.; Gerhauser, C.; Loidl, P., Amide analogues of

236

trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell
differentiation. J Med Chem 1999, 42 (22), 4669-79.
23.

(a) Hu, E.; Dul, E.; Sung, C. M.; Chen, Z.; Kirkpatrick, R.; Zhang, G. F.;

Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; de los Frailes, M.; Perez,
P.; Krawiec, J.; Winkler, J.; Jaye, M., Identification of novel isoform-selective inhibitors
within class I histone deacetylases. J Pharmacol Exp Ther 2003, 307 (2), 720-8; (b)
Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders,
K., Distinct pharmacological properties of second generation HDAC inhibitors with the
benzamide or hydroxamate head group. Int J Cancer 2007, 121 (5), 1138-48.
24.

(a) Hanessian, S.; Auzzas, L.; Giannini, G.; Marzi, M.; Cabri, W.; Barbarino, M.;

Vesci, L.; Pisano, C., Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of
HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett
2007, 17 (22), 6261-5; (b) Belvedere, S.; Witter, D. J.; Yan, J.; Secrist, J. P.; Richon, V.;
Miller, T. A., Aminosuberoyl hydroxamic acids (ASHAs): a potent new class of HDAC
inhibitors. Bioorg Med Chem Lett 2007, 17 (14), 3969-71.
25.

(a) Lavoie, R.; Bouchain, G.; Frechette, S.; Woo, S. H.; Abou-Khalil, E.; Leit, S.;

Fournel, M.; Yan, P. T.; Trachy-Bourget, M. C.; Beaulieu, C.; Li, Z.; Besterman, J.;
Delorme, D., Design and synthesis of a novel class of histone deacetylase inhibitors.
Bioorg Med Chem Lett 2001, 11 (21), 2847-50; (b) Varghese, S.; Senanayake, T.;
Murray-Stewart, T.; Doering, K.; Fraser, A.; Casero, R. A., Jr.; Woster, P. M.,
Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone
deacetylase inhibitors. J Med Chem 2008, 51 (8), 2447-56.

237

26.

Bieliauskas, A. V.; Weerasinghe, S. V.; Pflum, M. K., Structural requirements of

HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg
Med Chem Lett 2007, 17 (8), 2216-9.
27.

(a) Vinodhkumar, R.; Song, Y. S.; Ravikumar, V.; Ramakrishnan, G.; Devaki, T.,

Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix
metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).
Chem Biol Interact 2007, 165 (3), 220-9; (b) You, J. S.; Kang, J. K.; Lee, E. K.; Lee, J.
C.; Lee, S. H.; Jeon, Y. J.; Koh, D. H.; Ahn, S. H.; Seo, D. W.; Lee, H. Y.; Cho, E. J.;
Han,

J.

W.,

Histone

deacetylase

inhibitor

apicidin

downregulates

DNA

methyltransferase 1 expression and induces repressive histone modifications via
recruitment of corepressor complex to promoter region in human cervix cancer cells.
Oncogene 2008, 27 (10), 1376-86; (c) Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin,
S.; Yoshida, M.; Horinouchi, S., Potent histone deacetylase inhibitors built from
trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proceedings of the
National Academy of Sciences of the United States of America 2001, 98 (1), 87-92.
28.

Woo, S.; Gardner, E. R.; Chen, X.; Ockers, S. B.; Baum, C. E.; Sissung, T. M.;

Price, D. K.; Frye, R.; Piekarz, R. L.; Bates, S. E.; Figg, W. D., Population
pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and
relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009, 15 (4), 1496-503.
29.

Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K. H.; Nishiyama, M.; Nakajima,

H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S., FK228
(depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer
Res 2002, 62 (17), 4916-21.

238

30.

Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian,

X.; Mills, E.; Berghs, S. C.; Carey, N.; Finn, P. W.; Collins, L. S.; Tumber, A.; Ritchie, J.
W.; Jensen, P. B.; Lichenstein, H. S.; Sehested, M., Determination of the class and
isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008,
409 (2), 581-9.
31.

Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.;

Gallinari, P.; Ingenito, R.; Meinke, P. T.; Petrocchi, A.; Rowley, M.; Scarpelli, R.;
Serafini, S.; Steinkuhler, C., A series of novel, potent, and selective histone deacetylase
inhibitors. Bioorg Med Chem Lett 2006, 16 (23), 5948-52.
32.

Hanessian, S., Vorinostat-Like Molecules as Structural, Stereochemical, and

Pharmacological Tools. ACS Medicinal Chemistry Letters 2010, 1, 70-74.
33.

Spencer, J., Synthesis and Biological Evaluation of JAHAs: Ferrocene-Based

Histone Deacetylase Inhibitors. ACS Medicinal Chemistry Letters 2011, 2, 358-362.
34.

(a) Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.;

Mazitschek, R.; Kwiatkowski, N. P.; Lewis, T. A.; Maglathin, R. L.; McLean, T. H.;
Bochkarev, A.; Plotnikov, A. N.; Vedadi, M.; Arrowsmith, C. H., Human HDAC7 harbors
a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase
activity. J Biol Chem 2008, 283 (17), 11355-63; (b) Vannini, A.; Volpari, C.; Gallinari, P.;
Jones, P.; Mattu, M.; Carfi, A.; De Francesco, R.; Steinkuhler, C.; Di Marco, S.,
Substrate binding to histone deacetylases as shown by the crystal structure of the
HDAC8-substrate complex. EMBO Rep 2007, 8 (9), 879-84.
35.

Lemon, D. D.; Horn, T. R.; Cavasin, M. A.; Jeong, M. Y.; Haubold, K. W.; Long,

C. S.; Irwin, D. C.; McCune, S. A.; Chung, E.; Leinwand, L. A.; McKinsey, T. A., Cardiac

239

HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell
Cardiol 2011, 51 (1), 41-50.
36.

Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio,

A.; Altucci, L.; Loidl, P.; Brosch, G., Class II (IIa)-selective histone deacetylase
inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl
hydroxyamides. J Med Chem 2005, 48 (9), 3344-53.
37.

Butler, K. V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A. P.,

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor,
tubastatin A. J Am Chem Soc 2010, 132 (31), 10842-6.
38.

(a) Dai, Y.; Guo, Y.; Curtin, M. L.; Li, J.; Pease, L. J.; Guo, J.; Marcotte, P. A.;

Glaser, K. B.; Davidsen, S. K.; Michaelides, M. R., A novel series of histone deacetylase
inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med
Chem Lett 2003, 13 (21), 3817-20; (b) Remiszewski, S. W.; Sambucetti, L. C.; Bair, K.
W.; Bontempo, J.; Cesarz, D.; Chandramouli, N.; Chen, R.; Cheung, M.; CornellKennon, S.; Dean, K.; Diamantidis, G.; France, D.; Green, M. A.; Howell, K. L.; Kashi,
R.; Kwon, P.; Lassota, P.; Martin, M. S.; Mou, Y.; Perez, L. B.; Sharma, S.; Smith, T.;
Sorensen, E.; Taplin, F.; Trogani, N.; Versace, R.; Walker, H.; Weltchek-Engler, S.;
Wood, A.; Wu, A.; Atadja, P., N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of
human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl

]phenyl]-2-propenamide

(NVP-LAQ824). J Med Chem 2003, 46 (21), 4609-24.
39.

Gupta, S. P., Quantitative structure-activity relationship studies on zinc-

containing metalloproteinase inhibitors. Chem Rev 2007, 107 (7), 3042-87.

240

40.

Leung, D.; Abbenante, G.; Fairlie, D. P., Protease inhibitors: current status and

future prospects. J Med Chem 2000, 43 (3), 305-41.
41.

Hanessian, S.; Moitessier, N.; Gauchet, C.; Viau, M., N-Aryl sulfonyl

homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of
the S(1), S(1)', and S(2)' pockets. J Med Chem 2001, 44 (19), 3066-73.
42.

Bhansali, P.; Hanigan, C. L.; Casero, R. A.; Tillekeratne, L. M., Largazole and

analogues with modified metal-binding motifs targeting histone deacetylases: synthesis
and biological evaluation. J Med Chem 2011, 54 (21), 7453-63.
43.

Taori, K.; Paul, V. J.; Luesch, H., Structure and activity of largazole, a potent

antiproliferative agent from the Floridian marine cyanobacterium Symploca sp. J Am
Chem Soc 2008, 130 (6), 1806-7.
44.

Karagiannis, T. C.; El-Osta, A., Will broad-spectrum histone deacetylase

inhibitors be superseded by more specific compounds? Leukemia 2007, 21 (1), 61-5.
45.

(a) Krusche, C. A.; Wulfing, P.; Kersting, C.; Vloet, A.; Bocker, W.; Kiesel, L.;

Beier, H. M.; Alfer, J., Histone deacetylase-1 and -3 protein expression in human breast
cancer: a tissue microarray analysis. Breast Cancer Res Treat 2005, 90 (1), 15-23; (b)
Hirokawa, Y.; Arnold, M.; Nakajima, H.; Zalcberg, J.; Maruta, H., Signal therapy of
breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and
abrogates the tamoxifen-resistance. Cancer Biol Ther 2005, 4 (9), 956-60; (c) Fritsche,
P.; Seidler, B.; Schuler, S.; Schnieke, A.; Gottlicher, M.; Schmid, R. M.; Saur, D.;
Schneider, G., HDAC2 mediates therapeutic resistance of pancreatic cancer cells via
the BH3-only protein NOXA. Gut 2009, 58 (10), 1399-409; (d) Marshall, G. M.; Gherardi,
S.; Xu, N.; Neiron, Z.; Trahair, T.; Scarlett, C. J.; Chang, D. K.; Liu, P. Y.; Jankowski, K.;

241

Iraci, N.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Stossi, F.;
Katzenellenbogen, B. S.; Biankin, A. V.; Perini, G.; Liu, T., Transcriptional upregulation
of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 2010, 29
(44), 5957-68; (e) Xu, X.; Xie, C.; Edwards, H.; Zhou, H.; Buck, S. A.; Ge, Y., Inhibition
of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric
acute myeloid leukemia cells. PLoS One 2011, 6 (2), e17138.
46.

Liu, T.; Kapustin, G.; Etzkorn, F. A., Design and synthesis of a potent histone

deacetylase inhibitor. J Med Chem 2007, 50 (9), 2003-6.
47.

Choi, S. E.; Weerasinghe, S. V.; Pflum, M. K., The structural requirements of

histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the
C3 position display isoform selectivity. Bioorg Med Chem Lett 2011, 21 (12), 6139-42.
48.

Hanessian, S.; Chahal, N.; Giroux, S., Iterative synthesis of deoxypropionate

units: the inductor effect in acyclic conformation design. J Org Chem 2006, 71 (19),
7403-11.
49.

Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.;

Bradner, J. E.; Wiest, O., Structural origin of selectivity in class II-selective histone
deacetylase inhibitors. J Med Chem 2008, 51 (10), 2898-906.
50.

(a) Hideshima, T.; Bradner, J. E.; Wong, J.; Chauhan, D.; Richardson, P.;

Schreiber, S. L.; Anderson, K. C., Small-molecule inhibition of proteasome and
aggresome function induces synergistic antitumor activity in multiple myeloma.
Proceedings of the National Academy of Sciences of the United States of America
2005, 102 (24), 8567-72; (b) Namdar, M.; Perez, G.; Ngo, L.; Marks, P. A., Selective
inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes

242

transformed cells to anticancer agents. Proceedings of the National Academy of
Sciences of the United States of America 2010, 107 (46), 20003-8.
51.

http://www.enzolifesciences.com/BML-AK500/fluor-de-lys-hdac-fluorometric-

activity-assay-kit/.
52.

Choi, S. E.; Weerasinghe, S. V.; Pflum, M. K., The structural requirements of

histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the
C3 position display isoform selectivity. Bioorg Med Chem Lett 2011.
53.

Sun Ea Choi, S. V. W. W., and Mary Kay Pflum, The Structural Requirements of

Histone Deacetylase Inhibitors: Suberoylanilide Hydroxamic Acid Analogues Modified at
the C3 Position Display Isoform Selectivity. 2011.
54.

Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P.

A.; Breslow, R.; Pavletich, N. P., Structures of a histone deacetylase homologue bound
to the TSA and SAHA inhibitors. Nature 1999, 401 (6749), 188-93.
55.

Hanessian,

S.,

Design

and

synthesis

of

MMP

inhibitors

using

N-

arylsulfonylaziridine hydroxamic acids as constrained scaffolds. Tetrahedron 2001, 57,
6885-6900.
56.

Zacharie, B.; Moreau, N.; Dockendorff, C., A mild procedure for the reduction of

pyridine N-oxides to piperidines using ammonium formate. J Org Chem 2001, 66 (15),
5264-5.
57.

Moradei, O. M.; Mallais, T. C.; Frechette, S.; Paquin, I.; Tessier, P. E.; Leit, S. M.;

Fournel, M.; Bonfils, C.; Trachy-Bourget, M. C.; Liu, J.; Yan, T. P.; Lu, A. H.; Rahil, J.;
Wang, J.; Lefebvre, S.; Li, Z.; Vaisburg, A. F.; Besterman, J. M., Novel aminophenyl

243

benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J
Med Chem 2007, 50 (23), 5543-6.
58.

Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R., Crystal

structure of a bacterial class 2 histone deacetylase homologue. J Mol Biol 2005, 354
(1), 107-20.

244
ABSTRACT
THE STRUCTURAL REQUIREMENTS OF HISTONE DEACETYLASE
INHIBITORS: SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) ANALOGUES
MODIFIED AT C3, C6, AND C7 POSITIONS ENHANCE SELECTIVITY
by
SUN EA CHOI
May 2012
Advisor: Dr. Mary Kay H. Pflum
Major: Chemistry (Organic)
Degree: Doctor of Philosophy
Histone deacetylase (HDAC) proteins are targets for drug design towards
the treatment of cancers since overexpression of HDAC proteins is linked to
cancer. Several HDAC inhibitors, including the FDA approved drug suberoylanilide hydroxamic acid (SAHA, Vorinostat), have cleared clinical trials and
emerged as anti-cancer drugs. However, SAHA inhibits all of the 11 metal iondependent HDAC proteins. Therefore, we synthesized several libraries of small
molecule HDAC inhibitors based on SAHA to help understand the structural
requirements of inhibitory potency and isoform selectivity.
In previous work,
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near

the
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acid displayed decreased inhibitory activity compared to the parent compound,
SAHA. The lack of potency of the C2 library indicated that limited flexibility exists
in the HDAC active site near the hydroxamic acid. Therefore, we theorized the
substituents on the C3, C4, C5, C6, and C7 positions would display more potent
inhibition compared to the C2-SAHA library due to the more solvent exposed
location. Interestingly, while the C2-SAHA analogues containing any substituents
were poor potent, the C3-SAHA analogue with a methyl substituent displayed
potency. The potency of the remaining analogues decreased with increasing size
of the C3 substituents. Moreover, the C6-SAHA phenyl analogue even displayed
potency in the submicromolar range. Finally, most of the C7-SAHA analogues
displayed equal or greater potency compared to SAHA. The results indicate that
more flexibility in the HDAC active site exists closer to the capping group region
near the C6 and C7 positions, while only modest flexibility exists in the bottom of
the active site near the C2 and C3 positions.
After analyzing the potency of SAHA analogues, isoform selective
inhibition of the individual compounds was evaluated. Seven of the SAHA

HDAC1
HDAC3
HDAC6

80

analogues

demonstrated

selectivity.

The C3-SAHA

ethyl-substituted

60

Percentage (%)

Deacetylase activity

100

showed

40

HDAC6

20

0

SAHA

HDAC3
1a
n-butyl

1b
phenyl

1c
ethyl

1d
vinyl

1e
methyl

analogue

preference
over
even

HDAC1
though

for
and
it

displayed decreased potency.

246
The C6-SAHA analogues displayed diverse selectivity; the C6-SAHA methyl
variant displayed preference for class I, t-butyl variant showed a dual-HDAC1
and HDAC6 selectivity, and 2-ethylhexyl variant showed HDAC3-selectivity. The
C7-SAHA analogues displayed selective inhibition as well; the C7-SAHA
pyridylmethyl and anthracenylmethyl variants displayed a dual-HDAC1 and
HDAC6 selectivity, and naphthylmethyl variant showed HDAC3-selectivity. The
interesting potency and selectivity of linker-modified SAHA analogues suggest
that linker region substituents can be exploited in the design of new anti-cancer
drugs.
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